



(86) Date de dépôt PCT/PCT Filing Date: 2005/01/18
(87) Date publication PCT/PCT Publication Date: 2005/08/04
(45) Date de délivrance/Issue Date: 2015/12/29
(85) Entrée phase nationale/National Entry: 2006/07/14
(86) N° demande PCT/PCT Application No.: US 2005/001549
(87) N° publication PCT/PCT Publication No.: 2005/069913
(30) Priorités/Priorities: 2004/01/16 (US60/537,148);
2004/04/22 (US60/564,798)

(51) Cl.Int./Int.Cl. *C12N 15/10* (2006.01),
C12N 1/21 (2006.01), *C12N 15/63* (2006.01),
C12N 15/64 (2006.01), *C12N 15/67* (2006.01),
C12N 15/74 (2006.01)

(72) Inventeurs/Inventors:
RETALLACK, DIANE M., US;
SQUIRES, CHARLES H., US;
WATKINS, DAVID C., US;
GAERTNER, FRANK H., US;
LEE, STACEY LYNN, US;
SHUTTER, ROBERT, US

(73) Propriétaire/Owner:
PFENEX INC., US

(74) Agent: SIM & MCBURNEY

(54) Titre : EXPRESSION DE PROTEINES MAMMIFERES DANS PSEUDOMONAS FLUORESCENS
(54) Title: EXPRESSION OF MAMMALIAN PROTEINS IN PSEUDOMONAS FLUORESCENS

(57) **Abrégé/Abstract:**

The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances. Processes for improved production of isolated mammalian, particularly human, proteins are provided.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 August 2005 (04.08.2005)

PCT

(10) International Publication Number
WO 2005/069913 A3

(51) International Patent Classification⁷: **C12N 15/10**,
15/63, 15/64, 15/67, 15/74, 1/21

(21) International Application Number:
PCT/US2005/001549

(22) International Filing Date: 18 January 2005 (18.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/537,148 16 January 2004 (16.01.2004) US
60/564,798 22 April 2004 (22.04.2004) US

(71) Applicant (for all designated States except US): **DOW
GLOBAL TECHNOLOGIES INC.** [US/US]; Washing-
ton Street, 1790 Building, Midland, MI 48674 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RETALLACK,
Diane, M.** [US/US]; 13420 Carriage Road, Poway, CA
92064 (US). **SQUIRES, Charles, H.** [US/US]; 15547
Hidden Valley Drive, Poway, CA 92064 (US). **WATKINS,
David, C.** [GB/US]; 185 Shady Hill Drive, East Green-
wich, RI 02818 (US). **GAERTNER, Frank, H.** [US/US];
4461 Ocean Boulevard #36, San Diego, CA 92109 (US).
LEE, Stacey, Lynn [US/US]; 13831 Paseo Cardiel, San
Diego, CA 92129 (US). **SHUTTER, Robert** [US/US];
16350 Woodson View Road, Poway, CA 92064 (US).

(74) Agent: **KNOWLES, Sherry, M.**; King & Spalding LLP,
191 Peachtree Street, 45th Floor, Atlanta, GA 30303-1763
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
22 September 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: EXPRESSION OF MAMMALIAN PROTEINS IN PSEUDOMONAS FLUORESCENS

(57) Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseu-
domonad, particularly in a *Pseudomonas fluorescens* organism. The process improves production of mammalian proteins, particu-
larly human or human-derived proteins, over known expression systems such as *E. coli* in comparable circumstances. Processes for
improved production of isolated mammalian, particularly human, proteins are provided.



WO 2005/069913 A3

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

EXPRESSION OF MAMMALIAN PROTEINS IN *PSEUDOMONAS FLUORESCENS***REFERENCE TO PRIOR APPLICATIONS**

This application claims priority to U.S. Provisional Application Nos. 60/564,798,
5 entitled "Expression of Mammalian Proteins in *Pseudomonas fluorescens*," filed April 22,
2004, and 60/537,148, entitled "Protein Expression Systems," filed January 16, 2004.

FIELD OF THE INVENTION

The invention is a process for improved production of a recombinant mammalian
protein by expression in a Pseudomonad, particularly in a *Pseudomonas fluorescens*
10 organism. The process improves production of mammalian protein expression over known
expression systems.

BACKGROUND OF THE INVENTION

More than 325 million people worldwide have been helped by the more than 155
biotechnology drugs and vaccines approved by the U.S. Food and Drug Administration
15 (FDA). In addition, there are more than 370 biotech drug products and vaccines currently in
clinical trials targeting more than 200 diseases, including various cancers, Alzheimer's
disease, heart disease, diabetes, multiple sclerosis, AIDS and arthritis. Unlike traditional
small molecule therapeutics that are produced through classical chemical synthesis, proteins
are usually produced in living cells inefficiently and at high cost. Due to the high cost and
20 complexity, there is a shortage of manufacturing capacity for protein-based therapeutics.

The use of microbial cells to produce products has a very long history. As early as
1897, Buchner discovered that enzymes extracted from yeast are effective in converting sugar
into alcohol, leading to the production of key industrial chemicals using microorganisms. By
the 1940s, large-scale production of penicillin via fermentation was achieved. Techniques for
25 the insertion of foreign genes into bacteria were first developed in the early 1970s. Bacterial
production of commercially viable recombinant mammalian protein was first exploited in the
production of human insulin (Goeddel, et al., 1979a; Wong, 1997). Today fermentation and
cell culture underlie the bulk of the industry's production of alcohol, antibiotics, biochemicals
and therapeutic proteins. However, development and manufacturing of therapeutically useful

proteins has been hampered due, in large part, to the limitations of the current organisms used to express these exogenous proteins.

Prokaryotic vs. Eukaryotic Protein Expression

Although bacterial expression system are often used to produce recombinant
5 eukaryotic proteins, typically the proteins yielded differ significantly from their original counterparts. In general, it is a challenge to reproduce the eukaryotic secondary and tertiary structures in *E. coli* expression systems. At the same time, while the eukaryotic expression systems currently are better able to form the secondary and tertiary structures of recombinant eukaryotic proteins, the capacity of these systems to produce recombinant proteins in large
10 quantity is limited.

Post-translational modifications represent the most significant differences between prokaryotic and eukaryotic protein expression. Prokaryotes (i.e., bacteria) have a very simply cellular structure and no membrane-bound organelles. In eukaryotes, a protein is often modified after it is initially produced. These modifications, in many cases, are necessary to
15 convert the peptide into a functional form. Thus, even when existing bacterial expression systems produce a protein with the correct primary structure, the protein may not be post-translationally modified and is therefore often nonfunctional. Common modifications include disulfide bond formation, glycosylation, acetylation, acylation, phosphorylation, and gamma-carboxylation, all of which can regulate protein folding and biological activity. Bacterial
20 expression systems generally do not properly glycosylate, acetylate, acylate, phosphorylate, or gamma-carboxylate eukaryotic proteins.

Bacteria, such as *E. coli*, can form disulfide bonds, but the bonds are often formed in the incorrect configuration required for biological activity; therefore, denaturation and refolding is usually required to produce active eukaryotic proteins. Molecular chaperone
25 proteins are present in both prokaryotes and eukaryotes that facilitate the folding of other proteins. In the absence of such chaperones, unfolded or partially folded polypeptide chains are unstable within the cell, frequently folding incorrectly or aggregating into insoluble complexes. The binding of chaperones stabilizes these unfolded polypeptides, thereby preventing incorrect folding or aggregation and allowing the polypeptide chain to fold into its
30 correct conformation. However, chaperones differ in each type of cell, and can be differentially expressed based on extracellular conditions.

Problems With Current Expression Systems

Escherichia coli (*E. coli*) is the most widely and routinely used protein expression system. Production in *E. coli* is inexpensive, fast, and well characterized. Further, scale-up and harvesting is possible and cGMP production is well established. However, there are
5 significant limitations to the use of *E. coli*, which often prove difficult to overcome, particularly when expressing recombinant mammalian proteins.

Along with the limitations described above, the high-level expression of recombinant gene products in *E. coli* often results in the misfolding of the protein of interest and its subsequent degradation by cellular proteases or deposition into biologically inactive
10 aggregates known as inclusion bodies. Protein found in inclusion bodies typically must be extracted and renatured for activity, adding time and expense to the process. Typical renaturation methods involve attempts to dissolve the aggregate in concentrated denaturant, and subsequent removal of the denaturant by dilution. Some of the factors which have been suggested to be involved in inclusion body formation include the high local concentration of
15 protein; a reducing environment in the cytoplasm (*E. coli* cytoplasm has a high level of glutathione) preventing formation of disulfide bonds; lack of post-translational modifications, which can increase the protein solubility; improper interactions with chaperones and other enzymes involved in *in vivo* folding; intermolecular cross-linking via disulfide or other covalent bonds; and increased aggregation of folding intermediates due to their limited
20 solubility. It is probably a combination of these factors, as well as a limited availability of chaperones, which most commonly lead to the formation of inclusion bodies.

Yeast expression systems, such as *Saccharomyces cerevisiae* or *Pichia pastoris*, are also commonly used to produce proteins. These systems are well characterized, provide good expression levels and are relatively fast and inexpensive compared to other eukaryotic
25 expression systems. However, yeast can accomplish only limited post-translational protein modifications, the protein may need refolding, and harvesting of the protein can be a problem due to the characteristics of the cell wall.

Insect cell expression systems have also emerged as an attractive, but expensive, alternative as a protein expression system. Correctly folded proteins that are generally post-
30 translationally modified can sometimes be produced and extracellular expression has been

achieved. However, it is not as rapid as bacteria and yeast, and scale-up is generally challenging.

Mammalian cell expression systems, such as Chinese hamster ovary cells, are often used for complex protein expression. This system usually produces correctly folded proteins with the appropriate post-translational modifications and the proteins can be expressed extracellularly. However, the system is very expensive, scale-up is slow and often not feasible, and protein yields are lower than in any other system.

Pseudomonas fluorescens (P. fluorescens)

Pseudomonas fluorescens encompasses a group of common, nonpathogenic saprophytes that colonize soil, water and plant surface environments. *P. fluorescens* are extensively used in agricultural and industrial processes, including commercially for the production of non-mammalian industrial and agricultural proteins. Nonmammalian enzymes derived from *P. fluorescens* have been used to reduce environmental contamination, as detergent additives, and for stereoselective hydrolysis. Mycogen began expressing recombinant bacterial proteins in *P. fluorescens* in the mid-1980's and filed its first patent application on the expression of the *Bacillus thuringiensis* toxin in *P. fluorescens* on January 22, 1985 ("Cellular encapsulation of biological pesticides"). Between 1985 and 2004, Mycogen, later Dow Agro Sciences, as well as other companies, capitalized on the agricultural use of *P. fluorescens* in patent applications on the production of pesticidal, insecticidal, and nematocidal toxins, as well as on specific toxic sequences and genetic manipulation to enhance expression of these. Examples of patent applications directed to the expression of recombinant bacterial proteins in *P. fluorescens* include: U.S. Patent Nos. 3,844,893; 3,878,093, 4,169,010; 5,292,507; 5,558,862; 5,559,015; 5,610,044; 5,622,846; 5,643,774; 5,662,898; 5,677,127; 5,686,282; 3,844,893; 3,878,093; 4,169,010; 5,232,840; 5,292,507; 5,558,862; 5,559,015; 5,610,044; 5,622,846; 5,643,774; 5,662,898; 5,677,127; 5,686,282; 5,686,283; 5,698,425; 5,710,031; 5,728,574; 5,731,280; 5,741,663; 5,756,087; 5,766,926; 5,824,472; 5,869,038; 5,891,688; 5,952,208; 5,955,348; 6,051,383; 6,117,670; 6,184,440; 6,194,194; 6,268,549; 6,277,625; 6,329,172; 6,447,770; as well as PCT Publication Nos. WO 00/15761; WO 00/29604; WO 01/27258; WO 02/068660; WO 02/14551; WO 02/16940; WO 03/089455; WO 04/006657; WO 04/011628; WO 87/05937; WO 87/05938; WO 95/03395; WO 98/24919; WO 99/09834; and WO 99/53035.

On October 8, 2003, Dow AgroSciences filed PCT Publication No. 04/087864 entitled, "Amended Recombinant Cells (ARCs) for the Production and Delivery of Antiviral Agents, Adjuvants and Vaccine Accelerants". The application describes recombinant cells that can include at least one heterologous gene encoding a chemokine or a cytokine and the administration of such cells to a host to accelerate an immune response. The application demonstrates the production of bovine interferon- α and interferon- γ in *P. fluorescens*.

Dow Global Technologies currently has several pending patent applications in the area of use of *P. fluorescens* to produce recombinant proteins. PCT Application WO 03/068926 to Dow Global Technologies, filed February 13, 2003, entitled, "Over-Expression of Extremozyme Genes in *Pseudomonas* and Closely Related Bacteria" describes an expression system in which pseudomonads, specifically *P. fluorescens*, can be used as host cells for the production of extremozyme enzymes. These enzymes are typically ancient, found in prokaryotes, eukaryotes including fungi, yeast, lichen, protists and protozoa, algae and mosses, tardigrades and fish. The patent discloses that enzymes can be derived from certain extremophilic fungi and yeast, but are typically derived from extremophilic bacteria.

PCT publication No. WO 03/089455 to Dow Global Technologies, filed April 22, 2003, entitled "Low-Cost Production of Peptides" describes a method of producing small peptides, primarily antimicrobial peptides, as concatameric precursors in Pseudomonads, specifically *P. fluorescens*.

PCT publication No. WO 04/005221 to Dow Global Technologies, entitled "Benzoate and Antranilate Inducible Promoters" provides novel benzoate- or anthranilate-inducible promoters from *P. fluorescens*, as well as novel tandem promoters, variants and improved mutants thereof, that are useful for commercial prokaryotic fermentation systems.

U.S. Patent No. 5,232,840 to Monsanto Co. describes the use of novel ribosomal binding sites to enhance expression of certain proteins in prokaryotic cells. In one example, the cells are used to express porcine growth hormone in several organisms, including *E. coli*, *P. fluorescens*, and *P. putida*. The data shows that *P. fluorescens* is less efficient at expressing the growth hormone when compared to *E. coli*. In contrast, when expressing a bacterial protein, *P. fluorescens* is much more effective at protein production than *E. coli* under comparable conditions. In fact, *P. fluorescens* cells described in this patent produce

several-fold more bacterially-derived β -galactosidase than *E. coli* (compare table 4 to tables 1 and 2).

While progress has been made in the production of proteins of commercial
5 interest, a strong need remains to improve the capability and production level of recombinant mammalian, and in particular human, proteins.

Therefore, it is an object of an aspect of the present invention to provide a process for the production of recombinant mammalian, in particular human, proteins that can be isolated and purified for therapeutic use, and cells which can accomplish this
10 process.

It is a further object of an aspect of the present invention to provide improved processes for the production of active recombinant mammalian proteins, including complex mammalian proteins.

It is a further object of an aspect of the present invention to provide improved
15 processes for the production of high levels of recombinant mammalian, in particular human, proteins.

It is a further object of an aspect of the present invention to provide transformed organisms that provide high expression levels of soluble or insoluble recombinant mammalian proteins.

20 SUMMARY OF THE INVENTION

It has been discovered that *Pseudomonas fluorescens* is a superior organism for the production of recombinant proteins, and in particular recombinant mammalian proteins, such as recombinant human proteins. Based on these discoveries, the present invention provides a process of producing recombinant mammalian or mammalian-
25 derived proteins in *P. fluorescens*. In addition, the invention provides *P. fluorescens* transformed to produce recombinant mammalian, including human, proteins.

In one embodiment, the invention provides a process of producing a mammalian protein in a *P. fluorescens* organism in which the protein is produced at a higher level or concentration per cell or per liter of fermentation reaction than in an *E. coli* organism
30 under comparable conditions. In yet another embodiment, the invention provides a process of producing mammalian proteins in an *P. fluorescens* organism in a batch culture which produces higher amounts of protein per liter than a corresponding batch of recombinant *E. coli* organisms.

Comparable conditions or substantially comparable conditions particularly refers to expression of recombinant protein using the same operably linked transcriptional promoter and ribosomal binding site in different organisms, and using the same initial induction conditions. Comparable conditions can further include using the same vector and associated regulatory elements, including, but not limited to, enhancer sequences, termination sequences, and origin or replication sequences. Comparable conditions can also include the same total volume of cell fermentation reaction. Comparable conditions can also include the same concentration of total cells per liter of reaction. In one embodiment, the conditions also include total induction times (before measurement) that are similar or the same. However, in another embodiment, the induction times can vary depending on the organism. Specifically, *P. fluorescens* has a capacity for increased growth time over *E. coli* without reducing protein production, such that protein production can be measured in *P. fluorescens* at a time point at which *E. coli* cells are largely silent. One way to measure the comparable conditions is to compare the percentage of recombinant protein per total cell protein. The comparable conditions also do not require identical media for growth. The media can be adjusted to ensure optimal production for the individual organisms.

In another embodiment, the invention provides a process for producing recombinant mammalian proteins by producing the proteins in a *P. fluorescens* organism and isolating the produced protein. In one sub-embodiment, the process includes substantially purifying the protein. In one embodiment, the protein is derived from a human protein, or is humanized.

The invention also provides the use of *P. fluorescens* in at least the following embodiments:

- (i) the production of recombinant mammalian, including human, proteins present in the cell in a range of between 1 and 75 percent total cell protein (%tcp), or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (ii) the production of recombinant mammalian, including human, proteins that are soluble and present in the cytoplasm of the cell in a range of between 1 and 75 %tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;

- (iii) the production of recombinant mammalian, including human, proteins that are insoluble in the cytoplasm of the cell, in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- 5 (iv) the production of recombinant mammalian, including human, proteins that are soluble in the periplasm of the cell in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- 10 (v) the production of recombinant mammalian, including human, proteins that are insoluble in the periplasm in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- 15 (vi) the production of recombinant mammalian, including human, proteins in the cell in a range of between 1 and 75 %tcp, or particularly at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more, when grown at a cell density of at least 40g/L;
- (vii) the production of recombinant mammalian, including human, proteins present in the cell in an active form;
- 20 (viii) the production of multi-subunit recombinant mammalian, including human, proteins in active form;
- (ix) the production of recombinant mammalian, including human, proteins that are then isolated and purified; and
- (x) the production of recombinant mammalian, including human, proteins that are renatured.

25 In one embodiment, the recombinant mammalian protein is selected from the group consisting of a multi-subunit protein, a blood carrier protein, an enzyme, a full length antibody, an antibody fragment, or a transcriptional factor.

In another embodiment, the invention includes:

- 30 (i) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins at a higher level or concentration than a

corresponding *E. coli* organism when grown under substantially corresponding conditions;

- (ii) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins and peptides that are present in the cell in a range of between 1 and 75% tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (iii) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins that are present in the cell in active form;
- (iv) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins that are soluble in the cytoplasm of the cell in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (v) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins that are insoluble in the cytoplasm of the cell in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (vi) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins that are soluble in the periplasm of the cell in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (vii) *Pseudomonas fluorescens* organisms that are transformed to produce recombinant mammalian, including human, proteins that are insoluble in the periplasm of the cell in a range of between 1 and 75 % tcp or in particular, at least greater than approximately 5% tcp, 10% tcp, at least 15% tcp, at least 20% tcp or more;
- (viii) *Pseudomonas fluorescens* organisms that are transformed to produce multi-subunit recombinant mammalian, including human, proteins;
- (ix) *Pseudomonas fluorescens* organisms that are transformed to produce multi-subunit recombinant mammalian, including human, proteins present in the cell in active form.

In an alternative embodiment, a *Pseudomonas* organisms and closely related bacteria other than *fluorescens* are used as host cells in this invention, as described in more detail

below. In one embodiment, the host cell will be selected generally from the genus *Pseudomonas* and specifically from a nonpathogenic *Pseudomonas* species. Likewise, any *Pseudomonas fluorescens* strain can be used that accomplishes the desired inventive goal, including but not limited to strain MB101, or a strain that is modified to include at least one host-cell-expressible, inserted copy of at least one Lac repressor protein-encoding *lacI* transgene, such as MB214 and MB217. The *Pseudomonas* organism can also optionally be genetically modified to add or delete one or more genes to improve performance, processing, or other characteristics.

In one embodiment, the *Pseudomonas* organism is transformed with a nucleic acid encoding a recombinant mammalian protein selected from the group consisting of a multi-subunit protein, a blood carrier protein, an enzyme, a full length antibody, an antibody fragment, or a transcriptional factor. In one embodiment, the *P. fluorescens* organism expresses a recombinant mammalian protein selected from the group consisting of a multi-subunit protein, a blood carrier protein, an enzyme, a full length antibody, an antibody fragment, or a transcriptional factor.

The expressed recombinant mammalian or human protein will typically have a mass of at least about 1kD, and up to about 100, 200, 300, 400 or 500 kD, often between about 10kD and about 100kD, and usually greater than about 30kD.

In accordance with one aspect of the present invention, there is provided a method for producing a recombinant mammalian protein in a *Pseudomonas fluorescens* host cell comprising:

transforming a host cell with a nucleic acid encoding a recombinant mammalian protein;

growing the cell under conditions that allow expression of the recombinant mammalian protein, wherein the recombinant mammalian protein is present in the host cell in a soluble or insoluble form.

In accordance with another aspect of the present invention, there is provided a *Pseudomonas fluorescens* cell comprising a nucleic acid encoding a recombinant human peptide.

According to a further aspect, there is provided a method for producing a recombinant human or murine protein in a *Pseudomonas fluorescens* host cell comprising:

transforming a *Pseudomonas fluorescens* host cell with a nucleic acid encoding a recombinant human or murine protein; and

growing the cell under conditions that allow expression of the recombinant human or murine protein,

wherein the recombinant human or murine protein is present in the host cell in a soluble form, wherein the soluble recombinant human or murine protein is expressed at an increased level when compared to an expression level of the protein under substantially comparable conditions in an *E.coli* expression system, and wherein the recombinant human or murine protein is an antibody.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graph showing hu- γ -IFN purified from the soluble fraction of *P. fluorescens* samples displays activity comparable to a commercially available standard.

Figure 2 is a picture of an ELISA showing the activity of purified Gal13 in *P. fluorescens* and *E. coli*.

Figure 3 represents human growth hormone expression constructs. The amino acid sequence of human growth hormone lacking its native secretion signal sequence is shown in A. Plasmid constructs for expression in *P. fluorescens* (pDOW2400) and *E. coli* (412-001, hGH) are shown in B.

Figure 4 is a picture of an SDS-PAGE analysis of soluble and insoluble fractions of hGH expressed in *P. fluorescens* and *E. coli*. The time post-induction is denoted by I0, I24, I48, 0 or 3. The large arrows indicate the position of the 21 kDa hGH protein.

Figure 5 shows an SDS-PAGE analysis of the expression of γ -IFN in *E. coli* versus *P. fluorescens* cells. Soluble (S) and insoluble (I) fractions of samples taken at 0, 3, 24 and 48 hours post-induction (I0, etc.) were resolved. *E. coli* expressed γ -IFN is shown in panel A, *P. fluorescens* expressed γ -IFN is shown in panel B. 5uL of A575-20 samples were loaded onto a 10% Bis-Tris NuPAGE gel and resolved in 1X MES. Arrows indicate the position of the recombinant protein. Western analyses are shown in panels C (*E. coli*) and D (*P. fluorescens*).

Figure 6 shows the replacement of the BuiBui toxin gene with the BGI gene at the *Spe*I and *Xho*I sites of pMYC1803.

Figure 7 shows that all the transformants selected had the desired interferon insert, as verified by sequencing the inserted DNA.

Figure 8 represents the nucleotide sequence for the phosphate binding protein-gal2 single chain antibody fusion protein.

Figure 9 represents the amino acid sequence for the phosphate binding protein-gal2 single chain antibody fusion protein.

Figure 10 represents the nucleotide sequence for the phosphate binding protein-human growth hormone fusion protein.

Figure 11 represents the amino acid sequence for the phosphate binding protein-human growth hormone fusion protein.

DETAILED DESCRIPTION OF THE INVENTION

25 *Process for producing recombinant mammalian proteins*

The invention provides processes and transformed *Pseudomonas fluorescens* organisms that produce recombinant mammalian proteins.

In one embodiment, the invention provides a process for producing recombinant mammalian proteins by producing the proteins in a *P. fluorescens* organism and isolating the produced protein. The protein can be isolated after expression by techniques known in the art,

including, but not limited to, affinity chromatography, ion-exchange chromatography, antibody affinity, size-exclusion, or any other method that eliminates a substantial portion of the cellular debris from the protein. In one sub-embodiment, the process provides a substantially purified protein. The isolated protein can have activity similar to that of the native protein that it is derived from. The protein can be isolated in a correctly folded state or conformation, approximating that of the native protein, or can be further renatured or modified to put it into a correctly folded conformation. In one sub-embodiment, the protein is derived from a human protein, or is humanized. A "humanized" protein is typically a chimeric mammalian-type protein which is partially comprised of a human-derived protein sequence. Humanization is particularly useful in antibody production and the development of humanized antibodies has been extensively described, for example in U.S. Patent No. 6,800,738.

In one embodiment, expression of the protein by the host cell is followed by isolation of the protein. In another embodiment, the protein or peptide is purified. In an alternative embodiment, the protein is purified following isolation of the protein. Optionally the isolated or purified protein can be renatured or refolded in order to produce active proteins.

In another embodiment, the invention provides a process of producing a mammalian protein in a *P. fluorescens* organism in which the protein is produced at a higher level or concentration than in an *E. coli* organism. The suitability of *P. fluorescens* organisms for high level production of mammalian proteins was unexpected based on the lack of success in producing such proteins in these organisms in the prior art. The present inventors have found that these organisms are indeed capable of high levels of production of mammalian proteins, and typically express protein in higher yield or at higher levels than *E. coli* when tested in corresponding assays. In another embodiment, the invention provides a process of producing mammalian proteins in an *P. fluorescens* organism in a batch culture which produces higher amounts of protein per liter than a corresponding batch of recombinant *E. coli* organisms.

In some embodiments, processes are provided that include producing recombinant mammalian, including human, multi-subunit proteins in active form in *P. fluorescens*; producing recombinant mammalian blood carrier proteins, including human blood carrier proteins such as transferrin and albumin in *P. fluorescens*; producing recombinant mammalian enzymes, including recombinant mammalian enzymes in active form in *P. fluorescens*;

producing antibodies and antibody fragments, including single chain antibodies and Fab fragments in *P. fluorescens*; and producing recombinant mammalian, including human, transcriptional factors in *P. fluorescens*.

5 In one embodiment, the recombinant mammalian protein is produced as a multimer, or in a concatameric precursor, for example, in the form of at least two small peptide (1-15 amino acids) units in tandem. In an alternative embodiment, the recombinant mammalian protein is not produced as a multimer, or in concatameric precursors, but instead is produced as a single chain polypeptide.

Screening of biomolecules

10 A separate embodiment of the present invention provides *P. fluorescens* organisms in a process of screening libraries of mammalian biomolecules to identify at least one that exhibits a desired activity or property. The *P. fluorescens* cells can be transformed with a number of mammalian derived nucleic acids for which testing is desired, producing a library of transformed host cells. Upon expression, polypeptides encoded by at least some of the
15 nucleic acids are produced for testing either in cytoplasm or following recovery from the cell. Examples of activities and properties for which testing may be performed include: polypeptide expression level; polypeptide stability; and biocatalytic activities and properties. Illustrative examples of biocatalytic activities and properties include: enzymatic activities; protein interactions/binding; protein stabilization; substrate usage; product formation; reaction
20 conditions, such as pH, salinity, or reaction temperature; biocatalytic parameters for a given catalyzed reaction, such as K_m and V_{max} ; and stability behavior, such as thermostability and biocatalyst half-life. The test results obtained may be used to selected library member(s) for further development.

Protein expression

25 A key aspect of this invention is the expression of high levels of recombinant mammalian, for example human, proteins in a range of between 1 and 75 percent total cell protein (%tcp) by expression in *P. fluorescens* organisms. The expressed proteins can be soluble or insoluble while in the *P. fluorescens* cell. Such high levels of soluble or insoluble recombinant mammalian proteins can be an improvement over previously known mammalian

protein expression systems. In particular, high levels of recovered mammalian proteins in large scale fermentation reactions are not typically possible with known techniques.

In one embodiment, the invention provides expression levels of mammalian proteins that exceed those found in *E. coli* expression systems. In one embodiment, the concentration of recombinant protein in each cell is higher than that found in *E. coli* in comparative assays. In one embodiment, the level of recombinant protein as compared to total cell protein measured in the *P. fluorescens* expression system is higher than that of the same recombinant protein expressed in *E. coli*. In another embodiment, the level or amount of soluble protein in the *P. fluorescens* expression system described herein is higher than the level or amount of soluble recombinant protein in a comparable *E. coli* expression system. In another embodiment, the total amount of active protein is higher than the amount derived from an *E. coli* expression system. In a separate embodiment, the level of recombinant active protein as compared to total cell protein measured in the *P. fluorescens* expression system is higher than that of the same recombinant protein expressed in *E. coli*. In one embodiment, the level, concentration, or amount of protein expressed in *P. fluorescens* is at least 2x, at least 3x, at least 4x, at least 5x, at least 6x, at least 7x, at least 8x, at least 9x, at least 10x, or more the level, concentration, or amount of recombinant protein expressed in *E. coli* in comparable assays.

One of the benefits of *P. fluorescens* as an expression system is that the cells can be grown in large scale cultures without negatively impacting their capacity for protein production. This capacity exceeds that found in other bacterial systems, such as *E. coli*. In another embodiment, the process includes producing mammalian proteins in batch cultures in which the recombinant protein is produced at a higher total level in *P. fluorescens* than in *E. coli* batch cultures. In yet another embodiment, the invention provides a process of producing mammalian proteins in an *P. fluorescens* organism in a batch culture which produces higher amounts of protein per liter than a corresponding batch of recombinant *E. coli* organisms.

The invention generally provides processes and transformed *P. fluorescens* organisms that afford expression levels of 1-75% total cell protein (tcp) of soluble or insoluble recombinant mammalian proteins. The recombinant mammalian proteins expressed in the cell can be expressed in an active form. In other embodiments, the *P. fluorescens* provides at

least 1, 5, 10, 15, 20, 25, 30, 40, 50, 55, 60, 65, 70, or 75 % tcp of recombinant mammalian proteins.

These proteins can be soluble, and when soluble, can be present in the cytoplasm or periplasm of the cell during production. Soluble proteins are readily released from the cell by methods including, but not limited to, rupturing of the cell membrane by pressure (i.e. the “French” press method), or by lysozyme degradation of the cell membrane. Cells can typically also be lysed using detergents, such as non-ionic detergents. Proteins that are soluble can be further stabilized by adjusting components of the buffer, such as buffer pH, salt concentrations, or additional protein components (for example, in multi-subunit complexes).

The soluble proteins can be isolated or purified from other protein and cellular debris by, for example, centrifugation and/or chromatography such as size exclusion, anion or cation exchange, or affinity chromatography.

The proteins can also be insoluble. Insoluble proteins are typically found in inclusion bodies in the cytoplasm, but are also often in the periplasm. Not all insoluble proteins are in inclusion bodies, and can also be found in membrane aggregates, as small protein aggregates or in any other insoluble form in the cytoplasm or periplasm. Insoluble proteins can typically be renatured using, for example, reducing agents such as urea or guanidine hydrochloride. Insoluble proteins or protein aggregates can be isolated, for example, by centrifugation and/or chromatography such as size exclusion chromatography. Proteins in insoluble aggregates can typically be separated by solubilization of the aggregates using, for example, micelles or reverse micelles as described in Vinogradov, et al. (2003) *Anal Biochem.* 15;320(2):234-8.

In a particular embodiment, the *Pseudomonas* host cell can have a recombinant mammalian peptide, polypeptide, protein, or fragment thereof expression level of at least 1% tcp and a cell density of at least 40 g/L, when grown (i.e. within a temperature range of about 4° C to about 55° C, inclusive) in a mineral salts medium. In a particular embodiment, the expression system will have a recombinant protein of peptide, including recombinant mammalian protein, expression level of at least 5% tcp and a cell density of at least 40 g/L, when grown (i.e. within a temperature range of about 4° C to about 55° C, inclusive) in a mineral salts medium at a fermentation scale of at least 10 Liters.

Expression levels can be measured by standard techniques known in the art. In one embodiment, the amount of protein (in grams) is compared to the amount in grams of total

cell protein in a given sample. In another embodiment, the measurement is a level of recombinant protein per liter. In another embodiment, the level or amount can be measured as compared to a known standard, such as a BSA control. The level or amount of recombinant protein can be measured, for example, by analyzing the light absorbtion of a purified protein, by measuring an affinity of an marker for the protein (such as an antibody affinity) and comparing that to a known standard, or by measuring the level of activity compared to a known standard (such as a known amount of purified, active protein).

It has been found that, in certain situations, no additional disulfide-bond-promoting conditions or agents are required in order to recover disulfide-bond-containing target polypeptides in active, soluble form, when a *Pseudomonas fluorescens* bacteria is used as the expression host cell. Therefore, in one embodiment, the transgenic peptide, polypeptide, protein, or fragment contains at least one intramolecular disulfide bond in its native state. In other embodiments, the protein can contain up to 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20 or more disulfide bonds in its native state.

In some embodiments, the protein is expressed or found in the periplasm of the cell during production before purification or isolation. The protein can be secreted into the periplasm by being fused to an appropriate signal secretion sequence. In one embodiment, the signal sequence is a signal sequence that is native to the *P. fluorescens* genome. In specific embodiments, the signal sequence is a phosphate binding protein, a Lys-Arg-Orn binding protein (LAObp or KRObp) secretion signal peptide, an Outer Membrane Porin E (OpreE) secretion signal peptide, an azurin secretion signal peptide, an iron (III) binding protein (Fe(III)bp) secretion signal peptide, or a lipoprotein B (LprB) secretion signal peptide.

In one embodiment, the recombinant peptide, polypeptide, protein, or fragment thereof has a folded intramolecular conformation in its active state. *P. fluorescens* typically produce mammalian proteins more efficiently in the correctly folded conformation. In one embodiment, more than 50% of the expressed, transgenic peptide, polypeptide, protein, or fragment thereof produced can be produced as single peptides, polypeptides, proteins, or fragments thereof in soluble, active form or insoluble, but renaturable form in the cytoplasm or periplasm. In another embodiment about 60% , 70%, 75%, 80%, 85%, 90%, 95% of the expressed protein is obtained in or can be renatured into active form.

Definitions

Throughout this specification, the term "protein" is used to include any amino acid concatamers or polymers. The terms "polypeptide," "peptide" and "protein" are used interchangeably and include amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

The term "isolated" refers to nucleic acid, protein, or peptide that is substantially or essentially free from other material components which normally accompany it as found in its native state when in a cell, for example, other cellular components.

The term "purified" or "substantially purified" is used to mean that the protein is separated from other cell components and is separated from other proteins and peptides found in the cell that are not in a native complex with the protein. In particular embodiments, the purified proteins are of a purity approved for therapeutic or veterinary use as defined by standard cGMP guidelines or approved by the FDA.

The term "percent total cell protein" ("tcp") means the amount of protein in the host cell as a percentage of aggregate cellular protein. Alternatively, the term means a measure of the fraction of total cell protein that represents the relative amount of a given protein expressed by the cell.

The term "operably attached" refers to any configuration in which the transcriptional and any translational regulatory elements are covalently attached to the encoding sequence in such disposition(s), relative to the coding sequence, that in and by action of the host cell, the regulatory elements can direct the expression of the coding sequence.

As used herein, the term "mammal" is meant to include or designate any animal in the class Mammalia including human or non-human mammals, such as, but not limited, to porcine, ovine, bovine, rodents, ungulates, pigs, swine, sheep, lambs, goats, cattle, deer, mules, horses, monkeys, apes, dogs, cats, rats, and mice.

As used herein, the term "recombinant mammalian protein" or peptide is meant to include proteins derived from a native mammalian protein sequence or derived or generated from a native mammalian nucleic acid sequence. Such recombinant proteins can be produced from nucleic acid sequence substantially corresponding to native mammalian mRNA or

substantially corresponding cDNA, or fragments thereof. The sequence can be adjusted accordingly based on specific host cell codon usage as known in the art.

The phrase "substantially corresponding" in the context of two nucleic acids or polypeptides refers to the residues in the two sequences that have at least 50%, 60%, 70%, 80%, 90% or higher identity when aligned for maximum correspondence over a domain of the protein, as measured using an algorithms known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by algorithms known in the art (e.g. Smith & Waterman (1981) *Adv. Appl. Math.* 2:482; Needleman & Wunsch (1970) *J. Mol. Biol.* 48:443; Pearson & Lipman (1988) *Proc. Nat'l. Acad. Sci. USA* 85:2444; Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410 (BLAST)), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website.

The term "fragment" means a portion or partial sequence of a nucleotide, protein, or peptide sequence.

As used herein, the term "soluble" means that the protein is not precipitated by centrifugation at between approximately 5,000x and 20,000x gravity when spun for 10-30 minutes in a buffer under physiological conditions. Soluble proteins are not part of an inclusion body or other precipitated mass.

As used herein, the term "insoluble" means that the protein that can be precipitated by centrifugation at between 5,000x and 20,000x gravity when spun for 10-30 minutes in a buffer under physiological conditions. Insoluble proteins can be part of an inclusion body or other precipitated mass.

The term "inclusion body" is meant to include any intracellular body contained within a cell wherein an aggregate of proteins have been sequestered.

As used herein, the term "homologous" means either i) a protein that has an amino acid sequence that at least 70, 75, 80, 85, 90, 95, or 98% similar to the sequence of a given original protein and that retains a desired function of the original protein or ii) a nucleic acid that has a sequence that is at least 70, 75, 80, 5, 90, 95, or 98% similar to the sequence of a given nucleic acid and that retains a desired function of the original nucleic acid sequence. In

all of the embodiments of this invention and disclosure, any disclosed protein, peptide or nucleic acid can be substituted with a homologous or substantially homologous protein, peptide or nucleic acid that retains a desired function. In all of the embodiments of this invention and disclosure, when any nucleic acid is disclosed, it should be assumed that the invention also includes all nucleic acids that hybridize to the disclosed nucleic acid.

In one non-limiting embodiment, the non-identical amino acid sequence of the homologous polypeptide can be amino acids that are members of any one of the 15 conservative or semi-conservative groups shown in Table 1.

TABLE 1. *Similar Amino Acid Substitution Groups* -

Conservative Groups (8)	Semi-Conservative Groups (7)
Arg, Lys	Arg, Lys, His
Asp, Glu	Asn, Asp, Glu, Gln
Asn, Gln	
Ile, Leu, Val	Ile, Leu, Val, Met, Phe
Ala, Gly	Ala, Gly, Pro, Ser, Thr
Ser, Thr	Ser, Thr, Tyr
Phe, Tyr	Phe, Trp, Tyr
Cys (non-cystine), Ser	Cys (non-cystine), Ser, Thr

Types of Mammalian Proteins Produced

In general, the recombinant mammalian protein can be any mammalian protein of which an amino acid sequence is known or any putative mammalian or mammalian-derived protein for which an amino acid sequence is deduced. The proteins can be selected from the group consisting of a multi-subunit protein, a blood carrier protein, an enzyme, a full length antibody, an antibody fragment, or a transcriptional factor.

The amino acid sequence of the protein can be altered to adjust for desired qualities, such as to ensure certain types of interactions. The sequence can, for example, be adjusted to reduce immunoreactivity, or to increase absorption, reduce excretion, or otherwise enhance bioavailability in an organism such as a mammal. The amino acid sequence of the protein can thus be adjusted to ensure certain post-translational modifications or protein conformations.

In one embodiment, the mammalian protein is a chemokine or cytokine. In another embodiment, the mammalian proteins is one of the following proteins: IL-1, IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-12elasti, IL-13, IL-15, IL-16, IL-18, IL-18BP α , IL-23, IL-24, VIP, erythropoietin, GM-CSF, G-CSF, M-CSF,

platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF; e.g., aFGF (FGF-1), bFGF (FGF-2), FGF-3, FGF-4, FGF-5, FGF-6, or FGF-7), insulin-like growth factors (e.g., IGF-1, IGF-2); tumor necrosis factors (e.g., TNF, Lymphotoxin), nerve growth factors (e.g., NGF), vascular endothelial growth factor (VEGF); interferons (e.g., IFN- α , IFN- β , IFN- γ); leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); transforming growth factors (e.g., TGF- α , TGF- β 1, TGF- β 1, TGF- β 1); TNF superfamily (e.g., LIGHT/TNFSF14, STALL-1/TNFSF13B (BLy5, BAFF, THANK), TNF α /TNFSF2 and TWEAK/TNFSF12); or chemokines (BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GRO α /MGSA, HCC-1, I-TAC, Lymphotoxin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1/ABCD-1, MIP-1 α , MIP-1 β , MIP-2 α /GRO β , MIP-3 α /Exodus/LARC, MIP-3 α /Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1 α , TARC, or TECK).

Alternatively, the protein is not a chemokine or cytokine. In another embodiment, the mammalian protein is not one of the following proteins: IL-1, IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-12elasti, IL-13, IL-15, IL-16, IL-18, IL-18BP α , IL-23, IL-24, VIP, erythropoietin, GM-CSF, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF; e.g., aFGF (FGF-1), bFGF (FGF-2), FGF-3, FGF-4, FGF-5, FGF-6, or FGF-7), insulin-like growth factors (e.g., IGF-1, IGF-2); tumor necrosis factors (e.g., TNF, Lymphotoxin), nerve growth factors (e.g., NGF), vascular endothelial growth factor (VEGF); interferons (e.g., IFN- α , IFN- β , IFN- γ); leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); transforming growth factors (e.g., TGF- α , TGF- β 1, TGF- β 1, TGF- β 1); TNF superfamily (e.g., LIGHT/TNFSF14, STALL-1/TNFSF13B (BLy5, BAFF, THANK), TNF α /TNFSF2 and TWEAK/TNFSF12); or chemokines (BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GRO α /MGSA, HCC-1, I-TAC, Lymphotoxin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1/ABCD-1, MIP-1 α , MIP-1 β , MIP-2 α /GRO β , MIP-3 α /Exodus/LARC, MIP-3 α /Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1 α , TARC, or TECK). In one embodiment, the protein is not a porcine protein, particularly not a porcine growth factor.

As yet a further embodiment of the present disclosure, the recombinant mammalian proteins, their fragments or other derivatives, or analogs thereof, can be antibodies. These antibodies can be, for example, polyclonal or monoclonal antibodies. This aspect of the present invention also includes chimeric, single chain, and humanized antibodies, as well as
5 Fab fragments, or the product of an Fab expression library.

Production of Multi-subunit Proteins

In one embodiment of the present invention, the production of recombinant mammalian multi-subunit proteins by a host cell of the species *Pseudomonas* is provided. In another embodiment, a host cell of the *Pseudomonas* species is provided that has been
10 transformed to express a recombinant mammalian multi-subunit protein. In one embodiment, multisubunit proteins, including recombinant mammalian or human proteins, are expressed in a *Pseudomonas* host cell. In one embodiment, expression of the multi-subunit protein by the host cell is followed by isolation of the multi-subunit protein. In another embodiment, the multi-subunit protein of peptide is purified. The protein can be assembled by the cell before
15 purification or isolation, or further assembly can be undertaken during or after isolation or purification. Optionally, the protein or any portion thereof can be renatured or refolded to produce active proteins.

Any of a variety of vectors and expression systems can be used to express the multi-subunit protein in the host cell. The multi-subunits can be located on a single vector,
20 optionally operably linked to different promoters, optionally in a polycistronic sequence. Each subunit can also be on different vectors. Multiple vectors can be used. Each subunit can be under the control of one or more selection markers. Regulatory elements can be included on the vector, including periplasmic secretion signal sequences, internal ribosome entry sites, activator sequences, promoters, and termination signals.

25 In one embodiment, multisubunit proteins are expressed in *Pseudomonas* using expression systems with auxotrophic selection markers as disclosed in U.S. Application No. 10/994,138 to Dow Global Technologies filed November 19, 2004, wherein the control of each nucleic acid encoding a subunit is under the control of an auxotrophic selection marker. Multisubunit proteins that can be expressed include homomeric and heteromeric proteins.
30 The multisubunit proteins may include two or more subunits, that may be the same or different. For example, the protein may be a homomeric protein comprising 2, 3, 4, 5, 6, 7, 8,

9, 10, 11, 12 or more subunits. The protein also may be a heteromeric protein including 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more subunits.

Exemplary multisubunit mammalian proteins include: receptors including ion channel receptors; signaling proteins such as kinases, GTPases, ATPases; transmembrane proteins; 5 extracellular matrix proteins including chondroitin; collagen; immunomodulators including MHC proteins, full chain antibodies, and antibody fragments; enzymes including RNA polymerases, and DNA polymerases; and membrane proteins.

Production of Blood Proteins

In one embodiment of the present invention, the production of recombinant 10 mammalian blood proteins is provided. In one embodiment, expression of the blood protein by the host cell is followed by isolation of the blood protein. In another embodiment, the blood protein is purified. In another embodiment, following isolation of the blood protein, the blood protein is purified. Optionally, the protein can be renatured or refolded to produce active protein. In general, a recombinant blood protein of this invention is produced by 15 transforming a suitable host cell, such as a *P. fluorescens* host cell, with a nucleic acid construct encoding the blood protein, culturing the transformed host cell under conditions appropriate for expression, and optionally isolating, or isolating and purifying the recombinant blood protein expressed by the cell.

In another embodiment, a host cell of the *Pseudomonas* species is provided that has 20 been transformed to express a recombinant mammalian blood protein with an vector containing appropriate genes and regulatory elements for expression of the blood protein of interest is provided.

The blood proteins that can be expressed include, but are not limited to: carrier proteins, such as albumin, including human albumin (Seq ID No. 1, Table 2) and bovine 25 albumin; transferrin, including human transferrin (Seq ID No. 2, Table 2), bovine transferrin, rat transferrin, recombinant transferrin, recombinant transferrin half-molecules, recombinant transferrin half-molecules having altered properties; haptoglobin; fibrinogen and other coagulation factors; complement components; immunoglobulins; enzyme inhibitors; precursors of substances such as angiotensin and bradykinin; insulin; endothelin; globulin 30 including alpha, beta, and gamma-globulin; and other types of proteins, peptides, and fragments thereof found primarily in the blood of mammals. The amino acid sequences for

numerous blood proteins have been reported (see, S. S. Baldwin (1993) *Comp. Biochem Physiol.* 106b: 203-218), including the amino acid sequence for human serum albumin (Lawn, L.M., et al. (1981) *Nucleic Acids Research* 9:22; pp 6103-6114) and human serum transferrin (Yang, F. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81; pp. 2752-2756).

5 In a specific embodiment, the production of albumin in *P. fluorescens*, is provided, comprising transforming a *P. fluorescens* host cell with an expression vector containing a nucleic acid sequence or sequences and regulatory elements for expression of albumin, culturing the host cell under conditions suitable for expression of the albumin, and recovering the albumin expressed by *P. fluorescens*. According to this embodiment, the albumin
10 expressed is selected from the group consisting of human albumin, bovine albumin, rabbit albumin, chicken albumin, rat albumin, and mouse albumin. In another embodiment, albumin can be fused to a therapeutically active polypeptide, which can be of mammalian or non-mammalian origin.

In a further specific embodiment, the production of a transferrin in *P. fluorescens* is
15 provided, comprising transforming a *P. fluorescens* host cell with an expression vector containing nucleic acid and regulatory elements for expression of the transferrin, culturing the host cell under conditions suitable for expression of the transferrin. In another embodiment, following expression of the transferrin, and, in one embodiment, isolating the protein. In a further embodiment, the transferrin can be purified following isolation. The transferrin
20 expressed is selected from the group consisting of human serum transferrin, glycosylated human transferrin, non-glycosylated human transferrin, the N-terminal half-molecule of human transferrin, bovine transferrin, rat transferrin, mouse transferrin, primate transferrin, recombinant transferrin, recombinant transferrin half-molecules, recombinant transferrin half-molecules having altered properties, transferrin polynucleotides, transferrin polypeptides
25 encoded by transferrin polypeptides, transferrin polypeptides, transferrin antibodies, transferrin fragments, and transferrin fused to a therapeutically active polypeptide.

In yet another specific embodiment, the production of a globulin in *P. fluorescens* is provided, comprising transforming a *P. fluorescens* host cell with an expression vector containing nucleic acid and regulatory elements for expression of the globulin, culturing the
30 host cell under conditions suitable for expression of the globulin and optionally isolating the protein. In a further embodiment, following expression, the globulin is isolated and purified

from the host cell. The globulin expressed is selected from the group consisting of human globulin, bovine globulin, rabbit globulin, rat globulin, mouse globulin, sheep globulin, monkey globulin, steroid-binding globulins, and globulin fused to a therapeutically active polypeptide.

- 5 In a further embodiment, the production of an insulin in *P. fluorescens* is provided, comprising transforming a *P. fluorescens* host cell with an expression vector containing nucleic acid and regulatory elements for expression of the insulin, culturing the host cell under conditions suitable for expression of the insulin and optionally isolating the protein. In a further embodiment, the insulin can be isolated and purified following production of the
- 10 insulin by the host cell. The insulin expressed is selected from the group consisting of human insulin, bovine insulin, mouse insulin, rat insulin, porcine insulin, monkey insulin, and insulin fused to a therapeutically active polypeptide. The accession number for human insulin genes is J00265, and for synthetic human insulin gene the accession number is J02547.

- 15 Full-length DNA for production of recombinant blood proteins or truncated DNA encoding either the amino-terminal or carboxy-terminal lobe of blood proteins or a portion thereof can be obtained from available sources or can be synthesized according to the known sequences by standard procedures.

Table 2. Sequences of blood proteins expressed by the system of the present disclosure.

Amino Acid Sequence of human serum albumin	Seq. ID. No: 1	MKWVTFISLLFLFSSAYS SRGVFRRDAHKSEVAHRFKDLGE ENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVAD ESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQE PERNECFLQHKDDNP NLPRLVRPEVDVMCTAFHDNEETFL KKYLYEIARRHPYFYAPELLFFAKRYKAAFTTECCQAADKA ACLLPKLDEL RDEGKASSAKQRLK CASLQKFGERAFAKAW AVARLSQRFPKAEFAEVSKLVTDLT KVHTECCHGDLLECA DDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVEN DEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLY EY ARRHPDYSV VLLLRLAKTYETTLEKCCAAADPHECYAKV FDEFKPLVEEPQNLIKQNC ELFQQLGEYKFQNALLVRYTK KVPQVSTPTLVEVSRNLGKVGSKCKKHPEAKRMPCAEDY LSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALE VDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELV KHKPKATKEQLKAVMDDFAAFVEKCKADDKETCFAEE GKKLVAASQAALGL (Lawn, <i>et al.</i> (1981) <i>Nuc. Ac. Rsch.</i> 9(22):6103-6114)
Amino Acid	Seq. ID. No: 2	MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKC QSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIANEADA

Sequence of transferrin		VTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAV AVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYC DLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGC GCSTLNQYFGYSGAFKCLKNGAGDVAFVKHSTIFENLAN KARDRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARS MGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLF KDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCQEA PTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAET TEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENY NKSDNCEDTPEAGYFAVAVVKKASDLTWDNLKGKKSC HTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGAPGSKK DSSLCKLCMGSGNLNCEPNNKEGYGYGTGAFRCLVEKGD VAFVKHQTPQNTGGKNPDPWAKNLNEKDYELLCLDGT RKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQH LFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNT YEKYLGEFYVKA VGN L RKCSTSSLLEACTFRRP (Strausberg (2002) <i>PNAS</i> , 99:16899-16903)
cDNA Sequence of Human Insulin	Seq. ID. No: 3	atggccctgtggatgcgcctcctgcccctgctggcgctgctggccctctggggacctgacc cagccgcagccttctgaaccaacacctgtgcggctcacacctggtggaagctctctaccta gtgtgcggggaacgaggcttctctacacaccaagaccgccgggaggcagaggacct gcaggtggggcaggtggagctgggcggggccctggtgcaggcagcctgcagcccttg gccctggagggtccctgcagaagcgtggcattgtggaacaatgctgtaccagcatctgct ccctctaccagctggagaactactgcaactag

Production of Enzymes

In one embodiment of the present invention, the production of recombinant mammalian enzymes or co-factors by a host cell of the species *Pseudomonas fluorescens* is provided. In another embodiment, a host cell of the *Pseudomonas* species is provided that has
 5 been transformed to express a recombinant mammalian enzyme or co-factor.

The enzymes and co-factors expressed in this embodiment include but are not limited to aldolases, amine oxidases, amino acid oxidases, aspartases, B₁₂ dependent enzymes, carboxypeptidases, carboxyesterases, carboxylases, chemotrypsin, CoA requiring enzymes, cyanohydrin synthetases, cystathione synthases, decarboxylases, dehydrogenases, alcohol
 10 dehydrogenases, dehydratases, diaphorases, dioxygenases, enoate reductases, epoxide hydrases, fumerases, galactose oxidases, glucose isomerases, glucose oxidases, glycosyltransferases, methyltransferases, nitrile hydrases, nucleoside phosphorylases, oxidoreductases, oxynitilases, peptidases, glycosyltransferases, peroxidases, and enzymes fused to a therapeutically active polypeptide.

In another embodiment, the enzyme can be a mesophilic enzyme polypeptide, for example one that is desirable for human and/or veterinary therapeutic and/or diagnostic use. Examples of such therapeutic mesophilic enzymes include, e.g., tissue plasminogen activator; urokinase, reptilase, streptokinase; catalase, superoxide dismutase; DNase, amino acid
5 hydrolases (e.g., asparaginase, amidohydrolases); carboxypeptidases; proteases, trypsin, pepsin, chymotrypsin, papain, bromelain, collagenase; neuraminidase; lactase, maltase, sucrase, and arabinofuranosidases.

Yet another embodiment provides for the production of recombinant enzyme replacements in *P. fluorescens* cells by transforming a *P. fluorescens* host cell with an
10 expression vector containing nucleic acids and regulatory elements for expression of recombinant enzyme replacements, and culturing the cell under conditions suitable for expression of the recombinant enzyme replacements. The recombinant enzyme replacements expressed in the host cell is selected from the group consisting of Algasidase beta, Laronidase, and recombinant enzyme replacements fused to a therapeutically active
15 polypeptide.

Production of Mammalian Antibodies and Antibody Fragments

In one embodiment of the present invention, the production of recombinant mammalian single chain, Fab fragments and/or full chain antibodies or fragments or portions thereof by a host cell of the species *P. fluorescens* is provided. In one embodiment, following
20 expression of the protein, the protein can be isolated and optionally purified. Optionally, the protein can be renatured to produce an active protein. The antibody or antibody fragments are optionally linked to a secretion signal sequence for targeting in the cell during production.

In another embodiment, a host cell of the *Pseudomonas* species is provided that has been transformed to express a recombinant mammalian single chain, Fab fragments and/or
25 full chain antibodies or fragments or portions thereof.

In one embodiment, the *P. fluorescens* cell can produce a single chain antibody or fragments or portions thereof. A single-chain antibody can include the antigen-binding regions of antibodies on a single stably-folded polypeptide chain. Single-chain antibodies are of smaller size than classical immunoglobulins but can retain the antigen-specific binding
30 properties of antibodies. Single chain antibodies can be used for therapeutics, such as "naked" single-chain antibodies, bi-specific antibody binders, radioconjugates or as fusions with

effector domains, diagnostics, such as tumor imaging or in vivo or ex vivo cancer marker assays, research tools, such as protein purification and detection, including identification and characterization of novel therapeutic targets, antibody microarrays, display technologies and/or vehicles for gene or drug delivery.

5 In another embodiment, the *P. fluorescens* cell produces Fab fragments or portions thereof. Fab fragments can be a piece of a particular antibody. The Fab fragment can contain the antigen binding site. The Fab fragment can contains 2 chains : a light chain and a heavy chain fragment. These fragments can be linked via alinker or a disulfide bond.

10 In other embodiments of the present invention, full chain antibodies can be expressed in *P. fluorescens*, and other *Pseudomonas* species. An intact antibody containing the Fc region can be more resistant against degradation and clearance *in vivo*, thereby having longer biological half life in circulation. Such antibodies can be used as a therapeutic agent for diseases requiring sustained therapies.

15 In one embodiment, a process for producing a functional antibody or fragment thereof in *Pseudomonas* species is provided by providing an expression vector that contains separate cistronic or polycistronic sequences. The separate cistron expression vector can contain a first promoter-cistron pair for expression of an immunoglobulin light chain and a second promoter-cistron pair for expression of an immunoglobulin heavy chain, such that expression of the light chain and heavy chain are independently regulated by separate promoters. Each
20 cistron within the expression cassette polynucleotide can include a translation initiation region (TIR) operably linked to the nucleic acid sequence coding for the light chain or heavy chain of the full length antibody. In one embodiment, the TIR sequences can be manipulated to provide different translational strength combinations for light and heavy chains. In an alternative embodiment, a heavy chain coding sequence can be located on the same plasmid
25 as a light chain coding sequence. In an alternative embodiment, the heavy and light chain sequences are found in a polycistronic sequence within a single plasmid, or coded into the genome of the host.

In another embodiment, a process is provided for producing a functional antibody or fragment thereof in a host cell transformed with two separate translational units respectively
30 encoding the light and heavy chains of the antibody. In one embodiment the process includes:
a) culturing the host cell under suitable conditions so that the light chain and heavy chain are

expressed in a sequential fashion, thereby temporally separating the production of the light and heavy chains; and b) allowing the assembly of the light and heavy chains to form the functional antibody or fragment thereof.

In further embodiment, the *Pseudomonas* expression system can express human therapeutic single chain, Fab fragments or full chain antibodies or portions thereof, including, but not limited to Fab, Fab', F(ab')₂, F(ab')₂-leucine zipper, Fv, dsFv, anti-CD18 antibody, chimeric antibodies, human antibodies, humanized antibodies, or those described in the Table 3 below.

Table 3 – Antibodies and Antibody Fragments.

Antibody	Target Antigen	Product Type	Isotype	Indication
5G1.1	Complement (C5)	Humanised	IgG	Rheumatoid Arthritis
5G1.1	Complement (C5)	Humanised	IgG	SLE
5G1.1	Complement (C5)	Humanised	IgG	Nephritis
5G1.1-SC	Complement (C5)	Humanised	ScFv	Cardiopulmonary Bypass
5G1.1-SC	Complement (C5)	Humanised	ScFv	Myocardial Infarction
5G1.1-SC	Complement (C5)	Humanised	ScFv	Angioplasty
ABX-CBL	CBL	Human		GvHD
ABX-CBL	CD147	Murine	IgG	Allograft rejection
ABX-IL8	IL-8	Human	IgG2	Psoriasis
AD-159	gp120	Humanised		HIV
AD-439	gp120	Humanised		HIV
Antegren	VLA-4	Humanised	IgG	Multiple Sclerosis
Anti-CD11a	CD11a	Humanised	IgG1	Psoriasis
Anti-CD18	CD18	Humanised	Fab'2	Myocardial infarction
Anti-LFA1	CD18	Murine	Fab'2	Allograft rejection
Anti-VEGF	VEGF	Humanised	IgG1	Cancer (general
Antova	CD40L	Humanised	IgG	Allograft rejection
Antova	CD40L	Humanised	IgG	SLE
BEC2	anti-Id	Murine	IgG	Lung
BIRR-1	ICAM-1	Murine	IgG2a	Stroke
BTI-322	CD2	Rat	IgG	GvHD
C225	EGFR	Chimeric	IgG	Head+Neck
CAT-152	TGF-beta 2	Human		Glaucoma Surgery
CDP571	TNF-alpha	Humanised	IgG4	Crohn's
CDP571	TNF-alpha	Humanised	IgG4	Rheumatoid Arthritis
CDP850	E-selectin	Humanised		Psoriasis
Corsevin M	Fact VII	Chimeric		Anticoagulant
D2E7	TNF-alpha	Human		Rheumatoid Arthritis
Herceptin	Her2/neu	Humanised	IgG1	Metastatic Breast
HNK20	F gp	Murine	IgA	RSV

Hu23F2G	CD11/18	Humanised		Multiple Sclerosis
Hu23F2G	CD11/18	Humanised	IgG	Stroke
IC14	CD14	----		Toxic shock
ICM3	ICAM-3	Humanised		Psoriasis
IDEC-114	CD80	Primatised		Psoriasis
IDEC-131	CD40L	Humanised		SLE
IDEC-131	CD40L	Humanised		Multiple Sclerosis
IDEC-151	CD4	Primatised	IgG1	Rheumatoid Arthritis
IDEC-152	CD23	Primatised		Asthma/Allergy
Infliximab	TNF-alpha	Chimeric	IgG1	Rheumatoid Arthritis
Infliximab	TNF-alpha	Chimeric	IgG1	Crohn's
LDP-01	beta2-integrin	Humanised	IgG	Stroke
LDP-01	beta2-integrin	Humanised	IgG	Allograft rejection
LDP-02	alpha4beta7	Humanised		Ulcerative Colitis
LDP-03 / Campath1H	CD52	Humanised	IgG1	CLL
Lym-1	HLA DR	Chimeric		NHL
LympoCide	CD22	Humanised		NHL
MAK-195F	TNF alpha	Murine	Fab'2	Toxic shock
MDX-33	CD64 (FcR)	Human		Autoimmune haematological disorders
MDX-CD4	CD4	Human	IgG	Rheumatoid Arthritis
MEDI-500	TCR alpha beta	Murine	IgM	GvHD
MEDI-507	CD2	Humanised		Psoriasis
MEDI-507	CD2	Humanised		GvHD
OKT4A	CD4	Humanised	IgG	Allograft rejection
OrthoClone OKT4A	CD4	Humanised	IgG	Autoimmune disease
Orthoclone/ anti-CD3 OKT3	CD3	Murine	mIgG2 a	Allograft rejection
Ostavir	Hep B	Human		Hep B
OvaRex	CA 125	Murine		Ovarian
Panorex 17- 1A	EpCAM	Murine	IgG2a	Colorectal
PRO542	gp120	Humanised		HIV
Protovir	CMV	Humanised	IgG1	CMV
RepPro/Abc iximab	gpIIbIIIa	Chimeric	Fab	Complications of coronary angioplasty
rhuMab-E25	IgE	Humanised	IgG1	Asthma/Allergy
Rituxan	CD20	Chimeric	IgG1	NHL
SB-240563	IL5	Humanised		Asthma/Allergy
SB-240683	IL-4	Humanised		Asthma/Allergy
SCH55700	IL-5	Humanised		Asthma/Allergy
Simulect	CD25	Chimeric	IgG1	Allograft rejection

SMART a-CD3	CD3	Humanised		Autoimmune disease
SMART a-CD3	CD3	Humanised		Allograft rejection
SMART a-CD3	CD3	Humanised	IgG	Psoriasis
SMART M195	CD33	Humanised	IgG	AML
SMART 1D10	HLA	----		NHL
Synagis	F gp	Humanised	IgG1	RSV (Paediatric)
Vitaxin	VNRintegrin	Humanised		Sarcoma
Zenapax	CD25	Humanised	IgG1	Allograft rejection

Production of Transcriptional Factors

In one embodiment of the present invention, the production of recombinant mammalian transcription factors by a host cell of the species *Pseudomonas fluorescens* is provided. In one embodiment, following expression of the protein, the protein can be isolated. In another embodiment, the protein can be purified. Optionally, the protein can be renatured to produce an active protein. In another embodiment, a host cell of the *Pseudomonas* species is provided that has been transformed to express a recombinant mammalian transcription factor.

Transcription factors suitable for insertion into the expression systems of the present invention include those of the helix turn helix family and members of the Pac family, as well as other transcription factor families known in the art. Members of these families suitable for use with the present invention include mammalian and mammalian homologs and analogs of: transcriptional regulators; transcription factors of the of the ASNC family such as ASNC_trans_reg, putative transcriptional regulators; bacterial regulatory proteins of the luxR family; bacterial regulatory helix-turn-helix transcription factors; bacterial regulatory proteins of the arsR family; transcription factors of the helix-turn-helix domain, especially the rpiR family; bacterial regulatory protein transcription factors, bacterial regulatory helix-turn-helix transcription factors; DNA binding domain transcription factors; MarR family of transcription factors; the ROK family of transcription factors; the MerR family of regulatory proteins; arginine repressor transcription factors; firmicute transcriptional factors; ferric uptake regulatory transcription factors; sigma transcription factors; response regulatory receiver transcription factors; tryptophan RNA-binding attenuator protein transcription factors;

putative sugar-binding domain transcription factors; PRD domain transcription factors; nitrogen regulatory protein transcription factors; negative regulators of genetic competence, such as MecA; negative transcriptional regulator transcription factors; bacterial transcriptional regulator transcription factors; glycerol-3-phosphate responsive transcription factors; iron
5 dependent repressor transcription factors; and numerous species specific transcriptional regulator transcription factors.

Transcriptional factors expressed by *Pseudomonas* species can be utilized for diagnostic, therapeutic, and investigational applications.

Vector Preparation

10 Polynucleotides

The recombinant mammalian proteins and peptides can be expressed from polynucleotides in which the target polypeptide coding sequence is operably attached to transcription and translation regulatory elements forming a functional gene from which the host cell can express the protein. The coding sequence can be a native coding sequence for
15 the target polypeptide, if available, but can also be a coding sequence that has been selected, improved, or optimized for use in the selected expression host cell: for example, by synthesizing the gene to reflect the codon use bias of a *Pseudomonas* species such as *P. fluorescens*. The gene(s) that result will have been constructed within or will be inserted into one or more vector, which will then be transformed into the expression host cell. Nucleic acid
20 or a polynucleotide said to be provided in an "expressible form" means nucleic acid or a polynucleotide that contains at least one gene that can be expressed by the selected bacterial expression host cell.

Regulatory Elements

25 The regulatory elements used herein can be operably attached to the target recombinant mammalian protein encoding gene. The coding sequence of the protein-encoding gene used herein can contain, in addition to the mature polypeptide coding sequence and transcription-regulatory elements, further encoding elements, e.g., one or more of coding sequences for peptide tags, pre-peptides, pro-peptides, pre-pro-peptides, or other commonly
30 utilized encoding elements known in the art, excluding secretion signal peptides functional in the selected expression host cell.

The term "operably attached," as used herein, refers to any configuration in which the transcriptional and any translational regulatory elements are covalently attached to the coding sequence in such disposition(s), relative to the coding sequence, that the regulatory elements can direct the expression of the coding sequence. In one embodiment, the regulatory elements will be part of a whole gene before undergoing transformation into a host cell; however, in other embodiments the regulatory elements are part of another gene, which can be part of the host genome or can be part of a genome of another organism, or can be derived therefrom.

Promoters and Accessory Elements

The promoters used in accordance with the present invention may be constitutive promoters or regulated promoters. Common examples of useful regulated promoters include those of the family derived from the lac promoter (i.e. the lacZ promoter), especially the tac and trc promoters described in U.S. Patent No. 4,551,433 to DeBoer, as well as Ptac16, Ptac17, PtacII, PlacUV5, and the T7lac promoter.

Common examples of non-lac-type promoters useful in expression systems according to the present invention include, e.g., those listed in Table 4.

Table 4. Examples of non-lac Promoters

Promoter	Inducer
λP_R	High temperature
λP_L	High temperature
Pm	Alkyl- or halo-benzoates
Pu	Alkyl- or halo-toluenes
Psal	Salicylates

See, e.g.: J. Sanchez-Romero & V. De Lorenzo (1999) *Manual of Industrial Microbiology and Biotechnology* (A. Demain & J. Davies, eds.) pp.460-74 (ASM Press, Washington, D.C.); H. Schweizer (2001) *Current Opinion in Biotechnology* 12:439-445; and R. Slater & R. Williams (2000) *Molecular Biology and Biotechnology* (J. Walker & R. Rapley, eds.) pp.125-54. A promoter having the nucleotide sequence of a promoter native to the selected bacterial host cell may also be used to control expression of the transgene encoding the target polypeptide, e.g., a *Pseudomonas* anthranilate or benzoate operon promoter (Pant, Pben). Tandem promoters may also be used in which more than one

promoter is covalently attached to another, whether the same or different in sequence, e.g., a Pant-Pben tandem promoter (interpromoter hybrid) or a Plac-Plac tandem promoter.

Regulated promoters utilize promoter regulatory proteins in order to control transcription of the gene of which the promoter is a part. Where a regulated promoter is used
5 herein, a corresponding promoter regulatory protein will also be part of an expression system according to the present invention. Examples of promoter regulatory proteins include: activator proteins, e.g., *E. coli* catabolite activator protein, MalT protein; AraC family transcriptional activators; repressor proteins, e.g., *E. coli* LacI proteins; and dual-fuction regulatory proteins, e.g., *E. coli* NagC protein. Many regulated-promoter/promoter-
10 regulatory-protein pairs are known in the art.

Promoter regulatory proteins interact with an effector compound, i.e. a compound that reversibly or irreversibly associates with the regulatory protein so as to enable the protein to either release or bind to at least one DNA transcription regulatory region of the gene that is under the control of the promoter, thereby permitting or blocking the action of a transcriptase
15 enzyme in initiating transcription of the gene. Effector compounds are classified as either inducers or co-repressors, and these compounds include native effector compounds and gratuitous inducer compounds. Many regulated-promoter/promoter-regulatory-protein/effector-compound trios are known in the art. Although an effector compound can be used throughout the cell culture or fermentation, in one embodiment in which a regulated promoter
20 is used, after growth of a desired quantity or density of host cell biomass, an appropriate effector compound is added to the culture in order directly or indirectly result in expression of the desired target gene(s).

By way of example, where a lac family promoter is utilized, a *lacI* gene can also be present in the system. The *lacI* gene, which is (normally) a constitutively expressed gene,
25 encodes the Lac repressor protein (LacI protein) which binds to the lac operator of these promoters. Thus, where a lac family promoter is utilized, the *lacI* gene can also be included and expressed in the expression system. In the case of the lac promoter family members, e.g., the tac promoter, the effector compound is an inducer, such as a gratuitous inducer like IPTG (isopropyl- β -D-1-thiogalactopyranoside, also called "isopropylthiogalactoside").

30

Other Elements

Other regulatory elements can be included in an expression construct. Such elements include, but are not limited to, for example, transcriptional enhancer sequences, translational enhancer sequences, other promoters, activators, translational start and stop signals, transcription terminators, cistronic regulators, polycistronic regulators, tag sequences, such as
5 nucleotide sequence "tags" and "tag" peptide coding sequences, which facilitates identification, separation, purification, or isolation of an expressed polypeptide.

At a minimum, a protein-encoding gene according to the present invention can include, in addition to the mammalian protein coding sequence, the following regulatory elements operably linked thereto: a promoter, a ribosome binding site (RBS), a transcription
10 terminator, translational start and stop signals. Useful RBSs can be obtained from any of the species useful as host cells in expression systems, such as from the selected host cell. Many specific and a variety of consensus RBSs are known, e.g., those described in and referenced by D. Frishman et al. (1999) *Gene* 234(2):257-65; and B.E. Suzek et al. (2001) *Bioinformatics* 17(12):1123-30. In addition, either native or synthetic RBSs may be used, e.g., those
15 described in: EP 0207459 (synthetic RBSs); O. Ikehata et al. (1989) *Eur. J. Biochem.* 181(3):563-70 (native RBS sequence of AAGGAAG). Further examples of methods, vectors, and translation and transcription elements, and other elements useful in the present invention are described in, e.g.: U.S. Patent Nos. 5,055,294 and 5,128,130 to Gilroy et al.; 5,281,532 to Rammler et al.; 4,695,455 and 4,861,595 to Barnes et al.; 4,755,465 to Gray et al.; and
20 5,169,760 to Wilcox.

Vectors

Transcription of the DNA encoding the enzymes of the present invention by *Pseudomonas* is increased by inserting an enhancer sequence into the vector or plasmid.
25 Typical enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp in size that act on the promoter to increase its transcription. Examples include various *Pseudomonas* enhancers, as described elsewhere herein.

Generally, the recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the *Pseudomonas* host cell, e.g., the
30 antibiotic-free resistance genes of *P. fluorescens*, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters

can be derived from operons encoding the enzymes such as 3-phosphoglycerate kinase (PGK), acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and, in one embodiment, a leader sequence capable of directing secretion of the translated enzyme. Optionally, the heterologous sequence can encode a fusion enzyme including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for use with *P. fluorescens* in expressing enzymes are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.

Vectors are known in the art as useful for expressing recombinant proteins in host cells, and any of these may be used for expressing the genes according to the present invention. Such vectors include, e.g., plasmids, cosmids, and phage expression vectors. Examples of useful plasmid vectors include, but are not limited to, the expression plasmids pBBR1MCS, pDSK519, pKT240, pML122, pPS10, RK2, RK6, pRO1600, and RSF1010. Other examples of such useful vectors include those described by, e.g.: N. Hayase (1994) *Appl. Envir. Microbiol.* 60(9):3336-42; A.A. Lushnikov et al. (1985) *Basic Life Sci.* 30:657-62; S. Graupner & W. Wackernagel (2000) *Biomolec. Eng.* 17(1):11-16.; H.P. Schweizer (2001) *Curr. Opin. Biotech.* 12(5):439-45; M. Bagdasarian & K.N. Timmis (1982) *Curr. Topics Microbiol. Immunol.* 96:47-67; T. Ishii et al. (1994) *FEMS Microbiol. Lett.* 116(3):307-13; I.N. Olekhovich & Y.K. Fomichev (1994) *Gene* 140(1):63-65; M. Tsuda & T. Nakazawa (1993) *Gene* 136(1-2):257-62; C. Nieto et al. (1990) *Gene* 87(1):145-49; J.D. Jones & N. Gutterson (1987) *Gene* 61(3):299-306; M. Bagdasarian et al. (1981) *Gene* 16(1-3):237-47; H.P. Schweizer et al. (2001) *Genet. Eng. (NY)* 23:69-81; P. Mukhopadhyay et al. (1990) *J. Bact.* 172(1):477-80; D.O. Wood et al. (1981) *J. Bact.* 145(3):1448-51; and R. Holtwick et al. (2001) *Microbiology* 147(Pt 2):337-44.

Further examples of expression vectors that can be useful in *Pseudomonas* host cells include those listed in Table 5 as derived from the indicated replicons.

Table 5. Some Examples of Useful Expression Vectors

Replicon	Vector(s)
pPS10	PCN39, PCN51
RSF1010	pKT261-3
	pMMB66EH
	pEB8
	pPLGN1
	pMYC1050
RK2/RP1	pRK415
	pJB653
pRO1600	pUCP
	pBSP

The expression plasmid, RSF1010, is described, e.g., by F. Heffron et al. (1975) *Proc. Nat'l Acad. Sci. USA* 72(9):3623-27, and by K. Nagahari & K. Sakaguchi (1978) *J. Bact.* 133(3):1527-29. Plasmid RSF1010 and derivatives thereof are particularly useful vectors in the present invention. Exemplary, useful derivatives of RSF1010, which are known in the art, include, e.g., pKT212, pKT214, pKT231 and related plasmids, and pMYC1050 and related plasmids (see, e.g., U.S. Patent Nos. 5,527,883 and 5,840,554 to Thompson et al.), such as, e.g., pMYC1803. Plasmid pMYC1803 is derived from the RSF1010-based plasmid pTJS260 (see U.S. Patent No. 5,169,760 to Wilcox), which carries a regulated tetracycline resistance marker and the replication and mobilization loci from the RSF1010 plasmid. Other exemplary useful vectors include those described in U.S. Patent No. 4,680,264 to Puhler et al.

In a one embodiment, an expression plasmid is used as the expression vector. In another embodiment, RSF1010 or a derivative thereof is used as the expression vector. In still another embodiment, pMYC1050 or a derivative thereof, or pMYC1803 or a derivative thereof, is used as the expression vector.

The plasmid can be maintained in the host cell by use of a selection marker gene, also present in the plasmid. This may be an antibiotic resistance gene(s), in which case the corresponding antibiotic(s) will be added to the fermentation medium, or any other type of selection marker gene known as useful in the art, e.g., a prototrophy-restoring gene in which case the plasmid will be used in a host cell that is auxotrophic for the corresponding trait, e.g., a biocatalytic trait such as an amino acid biosynthesis or a nucleotide biosynthesis trait or a carbon source utilization trait.

Extensive sequence information required for molecular genetics and genetic engineering techniques is widely publicly available. Access to complete nucleotide sequences of mammalian, as well as human, genes, cDNA sequences, amino acid sequences and genomes can be obtained from GenBank. GenBank is maintained by the
 5 National Institutes of Health, Bethesda, MD, and can be accessed at ncbi.nlm.nih.gov/Entrez within the NIH website. Additional information can also be obtained from GeneCards, an electronic encyclopedia integrating information about genes and their products and biomedical applications, made available by the Department of Molecular Genetics, the Weizmann Institute of Science, Rehovot, Israel. Nucleotide
 10 sequence information also can be also obtained from the EMBL Nucleotide Sequence Database made available on the worldwide web by the European Bioinformatics Institute (Hinxton, Cambridge, UK) or the DNA Databank of Japan (Research Organization of Information and Systems, National Institute of Genetics, Center for Information Biology and DNA Data Bank of Japan, 1111 Yata, Mishima, Shizuoka 411-8540, Japan).
 15 Additional sites for information on amino acid sequences include the Protein Information Resource website established by the National Biomedical Research Foundation, which includes Swiss-Prot.

Transformation

Transformation of the *Pseudomonas* host cells with the vector(s) may be
 20 performed using any transformation methodology known in the art, and the bacterial host cells may be transformed as intact cells or as protoplasts (i.e. including cytoplasts). Exemplary transformation methodologies include poration methodologies, e.g., electroporation, protoplast fusion, bacterial conjugation, and divalent cation treatment, e.g., calcium chloride treatment or $\text{CaCl}/\text{Mg}^{2+}$ treatment, or other well known methods in
 25 the art. See, e.g., Morrison (1977) *J. Bact.* 132:349-351; Clark-Curtiss & Curtiss (1983) *Methods in Enzymology* 101:347-362, Sambrook *et al.* (1989) *Molecular Cloning, A Laboratory Manual* (2nd ed.); Kriegler (1990) *Gene Transfer and Expression: A Laboratory Manual*; and Ausubel *et al.*, eds. (1994) *Current Protocols in Molecular Biology*.

30 ***Pseudomonas* Organisms**

While the primary invention herein is the use of *Pseudomonas fluorescens*, other *Pseudomonas* and closely related bacterial organisms can be useful. *Pseudomonas* and closely related bacteria are generally part of the group defined as "Gram(-) Proteobacteria Subgroup 1" or "Gram-Negative Aerobic Rods and Cocci" (Buchanan and Gibbons (eds.)
 35 (1974) *Bergey's Manual of Determinative Bacteriology*, pp. 217-289).

Table 6. "Gram-Negative Aerobic Rods and Cocci" (Bergey (1974))

Family I. Pseudomonadaceae	<i>Gluconobacter</i> <i>Pseudomonas</i> <i>Xanthomonas</i> <i>Zoogloea</i>
Family II. Azotobacteraceae	<i>Azomonas</i> <i>Azotobacter</i> <i>Beijerinckia</i> <i>Derxia</i>
Family III. Rhizobiaceae	<i>Agrobacterium</i> <i>Rhizobium</i>
Family IV. Methylomonadaceae	<i>Methylococcus</i> <i>Methylomonas</i>
Family V. Halobacteriaceae	<i>Halobacterium</i> <i>Halococcus</i>
Other Genera	<i>Acetobacter</i> <i>Alcaligenes</i> <i>Bordetella</i> <i>Brucella</i> <i>Francisella</i> <i>Thermus</i>

"Gram-negative Proteobacteria Subgroup 1" also includes Proteobacteria that would be classified in this heading according to the criteria used in the classification. The heading also includes groups that were previously classified in this section but are no longer, such as the genera *Acidovorax*, *Brevundimonas*, *Burkholderia*, *Hydrogenophaga*, *Oceanimonas*, *Ralstonia*, and *Stenotrophomonas*, the genus *Sphingomonas* (and the genus *Blastomonas*, derived therefrom), which was created by regrouping organisms belonging to (and previously called species of) the genus *Xanthomonas*, the genus *Acidomonas*, which was created by regrouping organisms belonging to the genus *Acetobacter* as defined in Bergey (1974). In addition hosts can include cells from the genus *Pseudomonas*, *Pseudomonas enalia* (ATCC 14393), *Pseudomonas nigrifaciens* (ATCC 19375), and *Pseudomonas putrefaciens* (ATCC 8071), which have been reclassified respectively as *Alteromonas haloplanktis*, *Alteromonas nigrifaciens*, and *Alteromonas putrefaciens*. Similarly, e.g., *Pseudomonas acidovorans* (ATCC 15668) and *Pseudomonas testosteroni* (ATCC 11996) have since been reclassified as *Comamonas acidovorans* and *Comamonas testosteroni*, respectively; and *Pseudomonas nigrifaciens* (ATCC 19375) and *Pseudomonas piscicida* (ATCC 15057) have been reclassified respectively as *Pseudoalteromonas nigrifaciens* and *Pseudoalteromonas*

piscicida. "Gram-negative Proteobacteria Subgroup 1" also includes Proteobacteria classified as belonging to any of the families: Pseudomonadaceae, Azotobacteraceae (now often called by the synonym, the "Azotobacter group" of Pseudomonadaceae), Rhizobiaceae, and Methylomonadaceae (now often called by the synonym, "Methylococcaceae").

5 Consequently, in addition to those genera otherwise described herein, further Proteobacterial genera falling within "Gram-negative Proteobacteria Subgroup 1" include: 1) Azotobacter group bacteria of the genus *Azorhizophilus*; 2) Pseudomonadaceae family bacteria of the genera *Cellvibrio*, *Oligella*, and *Teredinibacter*; 3) Rhizobiaceae family bacteria of the genera *Chelatobacter*, *Ensifer*, *Liberibacter* (also called "*Candidatus Liberibacter*"), and
10 *Sinorhizobium*; and 4) Methylococcaceae family bacteria of the genera *Methylobacter*, *Methylocaldum*, *Methylomicrobium*, *Methylosarcina*, and *Methylosphaera*.

In another embodiment, the host cell is selected from "Gram-negative Proteobacteria Subgroup 2." "Gram-negative Proteobacteria Subgroup 2" is defined as the group of Proteobacteria of the following genera (with the total numbers of catalog-listed, publicly-
15 available, deposited strains thereof indicated in parenthesis, all deposited at ATCC, except as otherwise indicated): *Acidomonas* (2); *Acetobacter* (93); *Gluconobacter* (37); *Brevundimonas* (23); *Beijerinckia* (13); *Derxia* (2); *Brucella* (4); *Agrobacterium* (79); *Chelatobacter* (2); *Ensifer* (3); *Rhizobium* (144); *Sinorhizobium* (24); *Blastomonas* (1); *Sphingomonas* (27); *Alcaligenes* (88); *Bordetella* (43); *Burkholderia* (73); *Ralstonia* (33); *Acidovorax* (20);
20 *Hydrogenophaga* (9); *Zoogloea* (9); *Methylobacter* (2); *Methylocaldum* (1 at NCIMB); *Methylococcus* (2); *Methylomicrobium* (2); *Methylomonas* (9); *Methylosarcina* (1); *Methylosphaera*; *Azomonas* (9); *Azorhizophilus* (5); *Azotobacter* (64); *Cellvibrio* (3); *Oligella* (5); *Pseudomonas* (1139); *Francisella* (4); *Xanthomonas* (229); *Stenotrophomonas* (50); and *Oceanimonas* (4).

25 Exemplary host cell species of "Gram-negative Proteobacteria Subgroup 2" include, but are not limited to the following bacteria (with the ATCC or other deposit numbers of exemplary strain(s) thereof shown in parenthesis): *Acidomonas methanolica* (ATCC 43581); *Acetobacter aceti* (ATCC 15973); *Gluconobacter oxydans* (ATCC 19357); *Brevundimonas diminuta* (ATCC 11568); *Beijerinckia indica* (ATCC 9039 and ATCC 19361); *Derxia*
30 *gummosa* (ATCC 15994); *Brucella melitensis* (ATCC 23456), *Brucella abortus* (ATCC 23448); *Agrobacterium tumefaciens* (ATCC 23308), *Agrobacterium radiobacter* (ATCC

19358), *Agrobacterium rhizogenes* (ATCC 11325); *Chelatobacter heintzii* (ATCC 29600);
Ensifer adhaerens (ATCC 33212); *Rhizobium leguminosarum* (ATCC 10004); *Sinorhizobium*
fredii (ATCC 35423); *Blastomonas natatoria* (ATCC 35951); *Sphingomonas paucimobilis*
(ATCC 29837); *Alcaligenes faecalis* (ATCC 8750); *Bordetella pertussis* (ATCC 9797);
5 *Burkholderia cepacia* (ATCC 25416); *Ralstonia pickettii* (ATCC 27511); *Acidovorax facilis*
(ATCC 11228); *Hydrogenophaga flava* (ATCC 33667); *Zoogloea ramigera* (ATCC 19544);
Methylobacter luteus (ATCC 49878); *Methylocaldum gracile* (NCIMB 11912);
Methylococcus capsulatus (ATCC 19069); *Methylomicrobium agile* (ATCC 35068);
Methylomonas methanica (ATCC 35067); *Methylosarcina fibrata* (ATCC 700909);
10 *Methylosphaera hansonii* (ACAM 549); *Azomonas agilis* (ATCC 7494); *Azorhizophilus*
paspali (ATCC 23833); *Azotobacter chroococcum* (ATCC 9043); *Cellvibrio mixtus* (UQM
2601); *Oligella urethralis* (ATCC 17960); *Pseudomonas aeruginosa* (ATCC 10145),
Pseudomonas fluorescens (ATCC 35858); *Francisella tularensis* (ATCC 6223);
Stenotrophomonas maltophilia (ATCC 13637); *Xanthomonas campestris* (ATCC 33913); and
15 *Oceanimonas doudoroffii* (ATCC 27123).

In another embodiment, the host cell is selected from "Gram-negative Proteobacteria
Subgroup 3." "Gram-negative Proteobacteria Subgroup 3" is defined as the group of
Proteobacteria of the following genera: *Brevundimonas*; *Agrobacterium*; *Rhizobium*;
Sinorhizobium; *Blastomonas*; *Sphingomonas*; *Alcaligenes*; *Burkholderia*; *Ralstonia*;
20 *Acidovorax*; *Hydrogenophaga*; *Methylobacter*; *Methylocaldum*; *Methylococcus*;
Methylomicrobium; *Methylomonas*; *Methylosarcina*; *Methylosphaera*; *Azomonas*;
Azorhizophilus; *Azotobacter*; *Cellvibrio*; *Oligella*; *Pseudomonas*; *Teredinibacter*;
Francisella; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

In another embodiment, the host cell is selected from "Gram-negative Proteobacteria
25 Subgroup 4." "Gram-negative Proteobacteria Subgroup 4" is defined as the group of
Proteobacteria of the following genera: *Brevundimonas*; *Blastomonas*; *Sphingomonas* ;
Burkholderia; *Ralstonia*; *Acidovorax*; *Hydrogenophaga*; *Methylobacter*; *Methylocaldum*;
Methylococcus; *Methylomicrobium*; *Methylomonas*; *Methylosarcina*; *Methylosphaera*;
Azomonas; *Azorhizophilus*; *Azotobacter*; *Cellvibrio*; *Oligella*; *Pseudomonas*; *Teredinibacter*;
30 *Francisella* ; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

In an embodiment, the host cell is selected from "Gram-negative Proteobacteria Subgroup 5." "Gram-negative Proteobacteria Subgroup 5" is defined as the group of Proteobacteria of the following genera: *Methylobacter*; *Methylocaldum*; *Methylococcus*; *Methylomicrobium*; *Methylomonas*; *Methylosarcina*; *Methylosphaera*; *Azomonas*;
 5 *Azorhizophilus*; *Azotobacter*; *Cellvibrio*; *Oligella*; *Pseudomonas*; *Teredinibacter*; *Francisella*; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 6." "Gram-negative Proteobacteria Subgroup 6" is defined as the group of Proteobacteria of the following genera: *Brevundimonas*; *Blastomonas*; *Sphingomonas*; *Burkholderia*; *Ralstonia*;
 10 *Acidovorax*; *Hydrogenophaga*; *Azomonas*; *Azorhizophilus*; *Azotobacter*; *Cellvibrio*; *Oligella*; *Pseudomonas*; *Teredinibacter*; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 7." "Gram-negative Proteobacteria Subgroup 7" is defined as the group of Proteobacteria of the following genera: *Azomonas*; *Azorhizophilus*; *Azotobacter*; *Cellvibrio*; *Oligella*;
 15 *Pseudomonas*; *Teredinibacter*; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 8." "Gram-negative Proteobacteria Subgroup 8" is defined as the group of Proteobacteria of the following genera: *Brevundimonas*; *Blastomonas*; *Sphingomonas*; *Burkholderia*; *Ralstonia*;
 20 *Acidovorax*; *Hydrogenophaga*; *Pseudomonas*; *Stenotrophomonas*; *Xanthomonas*; and *Oceanimonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 9." "Gram-negative Proteobacteria Subgroup 9" is defined as the group of Proteobacteria of the following genera: *Brevundimonas*; *Burkholderia*; *Ralstonia*; *Acidovorax*; *Hydrogenophaga*;
Pseudomonas; *Stenotrophomonas*; and *Oceanimonas*.

25 The host cell can be selected from "Gram-negative Proteobacteria Subgroup 10." "Gram-negative Proteobacteria Subgroup 10" is defined as the group of Proteobacteria of the following genera: *Burkholderia*; *Ralstonia*; *Pseudomonas*; *Stenotrophomonas*; and *Xanthomonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 11." "Gram-negative Proteobacteria Subgroup 11" is defined as the group of Proteobacteria of the
 30 genera: *Pseudomonas*; *Stenotrophomonas*; and *Xanthomonas*. The host cell can be selected

from "Gram-negative Proteobacteria Subgroup 12." "Gram-negative Proteobacteria Subgroup 12" is defined as the group of Proteobacteria of the following genera: *Burkholderia*; *Ralstonia*; *Pseudomonas*. The host cell can be selected from "Gram-negative Proteobacteria Subgroup 13." "Gram-negative Proteobacteria Subgroup 13" is defined as the group of Proteobacteria of the following genera: *Burkholderia*; *Ralstonia*; *Pseudomonas*; and *Xanthomonas*. The host cell can be selected from "Gram-negative Proteobacteria Subgroup 14." "Gram-negative Proteobacteria Subgroup 14" is defined as the group of Proteobacteria of the following genera: *Pseudomonas* and *Xanthomonas*. The host cell can be selected from "Gram-negative Proteobacteria Subgroup 15." "Gram-negative Proteobacteria Subgroup 15" is defined as the group of Proteobacteria of the genus *Pseudomonas*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 16." "Gram-negative Proteobacteria Subgroup 16" is defined as the group of Proteobacteria of the following *Pseudomonas* species (with the ATCC or other deposit numbers of exemplary strain(s) shown in parenthesis): *P. abietaniphila* (ATCC 700689); *P. aeruginosa* (ATCC 10145); *P. alcaligenes* (ATCC 14909); *P. anguilliseptica* (ATCC 33660); *P. citronellolis* (ATCC 13674); *P. flavescens* (ATCC 51555); *P. mendocina* (ATCC 25411); *P. nitroreducens* (ATCC 33634); *P. oleovorans* (ATCC 8062); *P. pseudoalcaligenes* (ATCC 17440); *P. resinovorans* (ATCC 14235); *P. straminea* (ATCC 33636); *P. agarici* (ATCC 25941); *P. alcaliphila*; *P. alginovora*; *P. andersonii*; *P. asplenii* (ATCC 23835); *P. azelaica* (ATCC 27162); *P. beijerinckii* (ATCC 19372); *P. borealis*; *P. boreopolis* (ATCC 33662); *P. brassicacearum*; *P. butanovora* (ATCC 43655); *P. cellulosa* (ATCC 55703); *P. aurantiaca* (ATCC 33663); *P. chlororaphis* (ATCC 9446, ATCC 13985, ATCC 17418, ATCC 17461); *P. fragi* (ATCC 4973); *P. lundensis* (ATCC 49968); *P. taetrolens* (ATCC 4683); *P. cissicola* (ATCC 33616); *P. coronafaciens*; *P. diterpeniphila*; *P. elongata* (ATCC 10144); *P. flectens* (ATCC 12775); *P. azotoformans*; *P. brenneri*; *P. cedrella*; *P. corrugata* (ATCC 29736); *P. extremorientalis*; *P. fluorescens* (ATCC 35858); *P. gessardii*; *P. libanensis*; *P. mandelii* (ATCC 700871); *P. marginalis* (ATCC 10844); *P. migulae*; *P. mucidolens* (ATCC 4685); *P. orientalis*; *P. rhodesiae*; *P. synxantha* (ATCC 9890); *P. tolaasii* (ATCC 33618); *P. veronii* (ATCC 700474); *P. frederiksbergensis*; *P. geniculata* (ATCC 19374); *P. gingeri*; *P. graminis*; *P. grimontii*; *P. halodenitrificans*; *P. halophila*; *P. hibiscicola* (ATCC 19867); *P. huttiensis* (ATCC 14670); *P. hydrogenovora*; *P. jessenii* (ATCC 700870); *P. kilonensis*; *P.*

lanceolata (ATCC 14669); *P. lini*; *P. marginata* (ATCC 25417); *P. mephitica* (ATCC 33665); *P. denitrificans* (ATCC 19244); *P. pertucinogena* (ATCC 190); *P. pictorum* (ATCC 23328); *P. psychrophila*; *P. fulva* (ATCC 31418); *P. monteilii* (ATCC 700476); *P. mosselii*; *P. oryzihabitans* (ATCC 43272); *P. plecoglossicida* (ATCC 700383); *P. putida* (ATCC 12633); *P. reactans*; *P. spinosa* (ATCC 14606); *P. balearica*; *P. luteola* (ATCC 43273); *P. stutzeri* (ATCC 17588); *P. amygdali* (ATCC 33614); *P. avellanae* (ATCC 700331); *P. caricapapayae* (ATCC 33615); *P. cichorii* (ATCC 10857); *P. ficuserectae* (ATCC 35104); *P. fuscovaginae*; *P. meliae* (ATCC 33050); *P. syringae* (ATCC 19310); *P. viridiflava* (ATCC 13223); *P. thermocarboxydovorans* (ATCC 35961); *P. thermotolerans*; *P. thivervalensis*; *P. vancouverensis* (ATCC 700688); *P. wisconsinensis*; and *P. xiamenensis*.

The host cell can be selected from "Gram-negative Proteobacteria Subgroup 17." "Gram-negative Proteobacteria Subgroup 17" is defined as the group of Proteobacteria known in the art as the "fluorescent Pseudomonads" including those belonging, e.g., to the following *Pseudomonas* species: *P. azotoformans*; *P. brenneri*; *P. cedrella*; *P. corrugata*; *P. extremorientalis*; *Pseudomonas fluorescens*; *P. gessardii*; *P. libanensis*; *Pseudomonas mandelii*; *P. marginalis*; *P. migulae*; *P. mucidolens*; *P. orientalis*; *P. rhodesiae*; *P. synxantha*; *P. tolaasii*; and *P. veronii*.

The host cell can be selected from "Gram(-) Proteobacteria Subgroup 18." "Gram(-) Proteobacteria Subgroup 18" is defined as the group of all subspecies, varieties, strains, and other sub-special units of the species *P. fluorescens*, including those belonging, e.g., to the following (with the ATCC or other deposit numbers of exemplary strain(s) shown in parenthesis): *P. fluorescens* biotype A, also called biovar 1 or biovar I (ATCC 13525); *P. fluorescens* biotype B, also called biovar 2 or biovar II (ATCC 17816); *P. fluorescens* biotype C, also called biovar 3 or biovar III (ATCC 17400); *P. fluorescens* biotype F, also called biovar 4 or biovar IV (ATCC 12983); *P. fluorescens* biotype G, also called biovar 5 or biovar V (ATCC 17518); *P. fluorescens* biovar VI; *P. fluorescens* Pf0-1; *P. fluorescens* Pf-5 (ATCC BAA-477); *P. fluorescens* SBW25; and *P. fluorescens subsp. cellulosa* (NCIMB 10462).

The host cell can be selected from "Gram(-) Proteobacteria Subgroup 19." "Gram(-) Proteobacteria Subgroup 19" is defined as the group of all strains of *P. fluorescens* biotype A. A particular strain of this biotype is *P. fluorescens* strain MB101 (see US Patent No. 5,169,760 to Wilcox), and derivatives thereof. An example of a derivative thereof is *P.*

fluorescens strain MB214, constructed by inserting into the MB101 chromosomal *asd* (aspartate dehydrogenase gene) locus, a native *E. coli* PlacI-lacI-lacZYA construct (i.e. in which PlacZ was deleted).

In one embodiment, the host cell is any of the Proteobacteria of the order
5 Pseudomonadales. In a particular embodiment, the host cell is any of the Proteobacteria of the family Pseudomonadaceae.

Additional *P. fluorescens* strains that can be used in the present invention include *P. fluorescens* Migula and *P. fluorescens* Loitokitok, having the following ATCC designations: (NCIB 8286); NRRL B-1244; NCIB 8865 strain CO1; NCIB 8866 strain CO2; 1291 (ATCC
10 17458; IFO 15837; NCIB 8917; LA; NRRL B-1864; pyrrolidine; PW2 (ICMP 3966; NCPPB 967; NRRL B-899); 13475; NCTC 10038; NRRL B-1603 (6; IFO 15840); 52-1C; CCEB 488-A (BU 140); CCEB 553 (IEM 15/47); IAM 1008 (AHH-27); IAM 1055 (AHH-23); 1 (IFO 15842); 12 (ATCC 25323; NIH 11; den Dooren de Jong 216); 18 (IFO 15833; WRRL P-7); 93 (TR-10); 108 (52-22; IFO 15832); 143 (IFO 15836; PL); 149 (2-40-40; IFO 15838);
15 182 (IFO 3081; PJ 73); 184 (IFO 15830); 185 (W2 L-1); 186 (IFO 15829; PJ 79); 187 (NCPPB 263); 188 (NCPPB 316); 189 (PJ227; 1208); 191 (IFO 15834; PJ 236; 22/1); 194 (Klinge R-60; PJ 253); 196 (PJ 288); 197 (PJ 290); 198 (PJ 302); 201 (PJ 368); 202 (PJ 372); 203 (PJ 376); 204 (IFO 15835; PJ 682); 205 (PJ 686); 206 (PJ 692); 207 (PJ 693); 208 (PJ 722); 212 (PJ 832); 215 (PJ 849); 216 (PJ 885); 267 (B-9); 271 (B-1612); 401 (C71A; IFO
20 15831; PJ 187); NRRL B-3178 (4; IFO 15841); KY 8521; 3081; 30-21; (IFO 3081); N; PYR; PW; D946-B83 (BU 2183; FERM-P 3328); P-2563 (FERM-P 2894; IFO 13658); IAM-1126 (43F); M-1; A506 (A5-06); A505 (A5-05-1); A526 (A5-26); B69; 72; NRRL B-4290; PMW6 (NCIB 11615); SC 12936; A1 (IFO 15839); F 1847 (CDC-EB); F 1848 (CDC 93); NCIB 10586; P17; F-12; AmMS 257; PRA25; 6133D02; 6519E01; N1; SC15208; BNL-WVC;
25 NCTC 2583 (NCIB 8194); H13; 1013 (ATCC 11251; CCEB 295); IFO 3903; 1062; or Pf-5.

Fermentation

The term "fermentation" includes both embodiments in which literal fermentation is employed and embodiments in which other, non-fermentative culture modes are employed. Fermentation may be performed at any scale. In one embodiment, the fermentation medium
30 may be selected from among rich media, minimal media, and mineral salts media; a rich medium may be used, but is typically avoided. In another embodiment either a minimal

medium or a mineral salts medium is selected. In still another embodiment, a minimal medium is selected.

Mineral salts media consists of mineral salts and a carbon source such as, e.g., glucose, sucrose, or glycerol. Examples of mineral salts media include, e.g., M9 medium, *Pseudomonas* medium (ATCC 179), Davis and Mingioli medium (see, BD Davis & ES Mingioli (1950) *J. Bact.* 60:17-28). The mineral salts used to make mineral salts media include those selected from among, e.g., potassium phosphates, ammonium sulfate or chloride, magnesium sulfate or chloride, and trace minerals such as calcium chloride, borate, and sulfates of iron, copper, manganese, and zinc. Typically, no organic nitrogen source, such as peptone, tryptone, amino acids, or a yeast extract, is included in a mineral salts medium. Instead, an inorganic nitrogen source is used and this may be selected from among, e.g., ammonium salts, aqueous ammonia, and gaseous ammonia. A mineral salts medium will typically contain glucose as the carbon source. In comparison to mineral salts media, minimal media can also contain mineral salts and a carbon source, but can be supplemented with, e.g., low levels of amino acids, vitamins, peptones, or other ingredients, though these are added at very minimal levels.

In one embodiment, media can be prepared using the components listed in Table 7 below. The components can be added in the following order: first $(\text{NH}_4)\text{HPO}_4$, KH_2PO_4 and citric acid can be dissolved in approximately 30 liters of distilled water; then a solution of trace elements can be added, followed by the addition of an antifoam agent, such as Ucolub N 115. Then, after heat sterilization (such as at approximately 121°C), sterile solutions of glucose MgSO_4 and thiamine-HCL can be added. Control of pH at approximately 6.8 can be achieved using aqueous ammonia. Sterile distilled water can then be added to adjust the initial volume to 371 minus the glycerol stock (123 mL). The chemicals are commercially available from various suppliers, such as Merck. This media can allow for a high cell density cultivation (HCDC) for growth of *Pseudomonas* species and related bacteria. The HCDC can start as a batch process which is followed by a two-phase fed-batch cultivation. After unlimited growth in the batch part, growth can be controlled at a reduced specific growth rate over a period of 3 doubling times in which the biomass concentration can increased several fold. Further details of such cultivation procedures is described by Riesenber, D et al.

(1991) "High cell density cultivation of Escherichia coli at controlled specific growth rate" *J Biotechnol* 20(1):17-27.

Table 7: Medium composition

<u>Component</u>	<u>Initial concentration</u>
KH ₂ PO ₄	13.3 g l ⁻¹
(NH ₄) ₂ HPO ₄	4.0 g l ⁻¹
Citric acid	1.7 g l ⁻¹
MgSO ₄ ·7H ₂ O	1.2 g l ⁻¹
Trace metal solution	10 ml l ⁻¹
Thiamin HCl	4.5 mg l ⁻¹
Glucose-H ₂ O	27.3 g l ⁻¹
Antifoam Ucolub N115	0.1 ml l ⁻¹
<u>Feeding solution</u>	
MgSO ₄ ·7H ₂ O	19.7 g l ⁻¹
Glucose-H ₂ O	770 g l ⁻¹
NH ₃	23 g
<u>Trace metal solution</u>	
Fe(III) citrate	6 g l ⁻¹
MnCl ₂ ·4H ₂ O	1.5 g l ⁻¹
ZnCH ₂ COO l ₂ ·2H ₂ O	0.8 g l ⁻¹
H ₃ BO ₃	0.3 g l ⁻¹
Na ₂ MoO ₄ ·2H ₂ O	0.25 g l ⁻¹
CoCl ₂ 6H ₂ O	0.25 g l ⁻¹
CuCl ₂ 2H ₂ O	0.15 g l ⁻¹
ethylene	0.84 g l ⁻¹
dinitrilo-tetracetic acid Na ₂ ·2H ₂ O (Tritriplex III, Merck)	

5 The expression system according to the present invention can be cultured in any fermentation format. For example, batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein.

10 The expression systems according to the present invention are useful for transgene expression at any scale (i.e. volume) of fermentation. Thus, e.g., microliter-scale, centiliter scale, and deciliter scale fermentation volumes may be used; and 1 Liter scale and larger fermentation volumes can be used. In one embodiment, the fermentation volume will be at or above 1 Liter. In another embodiment, the fermentation volume will be at or above 5 Liters, 10 Liters, 15 Liters, 20 Liters, 25 Liters, 50 Liters, 75 Liters, 100 Liters, 200 Liters, 500 Liters, 1,000 Liters, 2,000 Liters, 5,000 Liters, 10,000 Liters or 50,000 Liters.

In the present invention, growth, culturing, and/or fermentation of the transformed host cells is performed within a temperature range permitting survival of the host cells, such as a temperature within the range of about 4°C to about 55°C, inclusive. In addition, "growth" is used to indicate both biological states of active cell division and/or enlargement, as well as biological states in which a non-dividing and/or non-enlarging cell is being metabolically sustained, the latter use being synonymous with the term "maintenance."

Cell Density

An additional advantage in using *P. fluorescens* in expressing recombinant mammalian proteins includes the capacity of *P. fluorescens* to be grown in high cell densities compared to *E. coli* or other bacterial expression systems. To this end, *P. fluorescens* expressions systems according to the present invention can provide a cell density of about 20 g/L or more. The *P. fluorescens* expressions systems according to the present invention can likewise provide a cell density of at least about 70 g/L, as stated in terms of biomass per volume, the biomass being measured as dry cell weight.

In one embodiment, the cell density will be at least 20 g/L. In another embodiment, the cell density will be at least 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, or at least 150 g/L.

In another embodiments, the cell density at induction will be between 20 g/L and 150 g/L, 20 g/L and 120 g/L; 20 g/L and 80 g/L; 25 g/L and 80 g/L; 30 g/L and 80 g/L; 35 g/L and 80 g/L; 40 g/L and 80 g/L; 45 g/L and 80 g/L; 50 g/L and 80 g/L; 50 g/L and 75 g/L; 50 g/L and 70 g/L; 40 g/L and 80 g/L.

Isolation and Purification

The proteins of this invention may be isolated purified to substantial purity by standard techniques well known in the art, including including, but not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, detergent solubilization, selective precipitation with such substances as column chromatography, immunopurification methods, and others. For example, proteins having established molecular adhesion properties

can be reversibly fused a ligand.. With the appropriate ligand, the protein can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. In addition, protein can be purified using immunoaffinity columns or Ni-NTA columns. General techniques are further described in, for example, R. Scopes (1982) *Protein Purification: Principles and Practice*, Springer-Verlag: N.Y.; Deutscher (1990) *Guide to Protein Purification*, Academic Press; U.S. Patent No. 4,511,503; S. Roe (2001) *Protein Purification Techniques: A Practical Approach*, Oxford Press; D. Bollag, et al. (1996) *Protein Methods*, Wiley-Lisa, Inc.; AK Patra et al. (2000) *Protein Expr Purif*, 18(2):182-92; and R. Mukhija, et al. (1995) *Gene* 165(2):303-6.

See also, for example, Deutscher (1990) "Guide to Protein Purification," *Methods in Enzymology* vol. 182, and other volumes in this series; Coligan, et al. (1996 and periodic Supplements) *Current Protocols in Protein Science*, Wiley/Greene, NY; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, Calif. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See also, for example: Hochuli (1989) *Chemische Industrie* 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) *Genetic Engineering, Principle and Methods* 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) *QIAexpress: The High Level Expression & Protein Purification System* QUIAGEN, Inc., Chatsworth, Calif.

Detection of the expressed protein is achieved by methods known in the art and include, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.

The recombinantly produced and expressed enzyme can be recovered and purified from the recombinant cell cultures by numerous methods, for example, high performance liquid chromatography (HPLC) can be employed for final purification steps, as necessary.

Certain proteins expressed in this invention may form insoluble aggregates ("inclusion bodies"). Several protocols are suitable for purification of proteins from inclusion bodies. For example, purification of inclusion bodies typically involves the extraction, separation and/or purification of inclusion bodies by disruption of the host cells, e.g., by incubation in a buffer of 50 mM TRIS/HCl pH 7.5, 50 mM NaCl, 5 mM MgCl₂, 1 mM DTT, 0.1 mM ATP,

and 1 mM PMSF. The cell suspension is typically lysed using 2-3 passages through a French Press. The cell suspension can also be homogenized using a Polytron (Brinkman Instruments) or sonicated on ice. Alternate methods of lysing bacteria are apparent to those of skill in the art (see, e.g., Sambrook, J., E. F. Fritsch and T. Maniatis eds. (1989) "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press; Ausubel et al., eds. (1994) *Current Protocols in Molecular Biology*).

If necessary, the inclusion bodies can be solubilized, and the lysed cell suspension typically can be centrifuged to remove unwanted insoluble matter. Proteins that formed the inclusion bodies may be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein. Other suitable buffers are known to those skilled in the art.

Alternatively, it is possible to purify the recombinant proteins from the host periplasm. After lysis of the host cell, when the recombinant protein is exported into the periplasm of the host cell, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to those skilled in the art. To isolate recombinant proteins from the periplasm, for example, the bacterial cells can be centrifuged to form a pellet. The pellet can be resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria can be centrifuged and the pellet can be resuspended in ice-cold 5 mM MgSO₄ and kept in an ice bath for approximately 10 minutes. The cell suspension can be centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.

An initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. One such example can be ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to

precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

The molecular weight of a recombinant protein can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture can be ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration can then be ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

Recombinant protiens can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).

Renaturation and Refolding

Insoluble protein can be renatured or refolded to generate secondary and tieriary protein structure conformation. Protein refolding steps can be used, as necessary, in completing configuration of the recombinant product. Refolding and renaturation can be accomplished using an agent that is known in the art to promote dissociation/association of proteins. For example, the proteincan be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.

Recombinant protein can also be renatured, for example, by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be refolded while immobilized on a column, such as the Ni-NTA column by using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation can be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole can be removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein can be stored at 4°C or frozen at -80°C.

Other methods include, for example, those that may be described in: MH Lee et al. (2002) *Protein Expr. Purif.* 25(1):166-73; W.K. Cho et al. (2000) *J. Biotechnology* 77(2-3):169-78; Deutscher (1990) "Guide to Protein Purification," *Methods in Enzymology* vol. 182, and other volumes in this series; Coligan, et al. (1996 and periodic Supplements) *Current Protocols in Protein Science*, Wiley/Greene, NY; S. Roe (2001) *Protein Purification Techniques: A Practical Approach*, Oxford Press; D. Bollag, et al. (1996) *Protein Methods*, Wiley-Lisa, Inc.

Active Protein or Peptide Analysis

Typically, an "active" protein includes proteins that have a biological function or biological effect comparable to the corresponding native protein. In the context of proteins this typically means that a polynucleotide or polypeptide comprises a biological function or effect that has at least about 20%, about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98% or 100% biological function compared to the corresponding native protein using standard parameters. The determination of protein activity can be performed utilizing corresponding standard, targeted comparative biological assays for particular proteins. One indication that a recombinant protein biological function or effect is that the recombinant polypeptide is immunologically cross reactive with the native polypeptide.

Active proteins typically have a specific activity of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% that of the native mammalian protein. Further, the substrate specificity (k_{cat}/K_m) is optionally substantially similar to the native mammalian protein. Typically, k_{cat}/K_m will be at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% that of the native

protein. Methods of assaying and quantifying measures of protein and peptide activity and substrate specificity (k_{cat}/K_m), are well known to those of skill in the art.

The activity of a recombinant mammalian protein can be measured by any protein specific conventional or standard *in vitro* or *in vivo* assay known in the art. The activity of the
5 *Pseudomonas* produced recombinant mammalian protein can be compared with the activity of the corresponding native mammalian protein to determine whether the recombinant mammalian protein exhibits substantially similar or equivalent activity to the activity generally observed in the native protein under the same or similar physiological conditions.

The activity of the recombinant protein can be compared with a previously established
10 native protein standard activity. Alternatively, the activity of the recombinant protein can be determined in a simultaneous, or substantially simultaneous, comparative assay with the native protein. For example, an *in vitro* assays can be used to determine any detectable interaction between a recombinant protein and a target, e.g. between an expressed enzyme and substrate, between expressed hormone and hormone receptor, between expressed antibody
15 and antigen, etc. Such detection can include the measurement of colorimetric changes, proliferation changes, cell death, cell repelling, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion methods, phosphorylation abilities, antibody specificity assays such as ELISA assays, etc. In addition, *in vivo* assays include, but are not limited to, assays to detect physiological effects of
20 the *Pseudomonas* produced protein in comparison to physiological effects of the native protein, e.g. weight gain, change in electrolyte balance, change in blood clotting time, changes in clot dissolution and the induction of antigenic response. Generally, any *in vitro* or *in vivo* assay can be used to determine the active nature of the *Pseudomonas* produced recombinant mammalian protein that allows for a comparative analysis to the native protein so long as
25 such activity is assayable. Alternatively, the proteins produced in the present invention can be assayed for the ability to stimulate or inhibit interaction between the protein and a molecule that normally interacts with the protein, e.g. a substrate or a component of the signal pathway that the native protein normally interacts. Such assays can typically include the steps of combining the protein with a substrate molecule under conditions that allow the protein to
30 interact with the target molecule, and detect the biochemical consequence of the interaction with the protein and the target molecule.

Assays that can be utilized to determine protein activity are described, for example, in: Ralph, P. J., et al. (1984) *J. Immunol.* 132:1858; Saiki et al. (1981) *J. Immunol.* 127:1044; Steward, W. E. II (1980) *The Interferon Systems*. Springer-Verlag, Vienna and New York; Broxmeyer, H. E., et al. (1982) *Blood* 60:595; Sambrook, J., E. F. Fritsch and T. Maniatis eds. (1989) "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press; Berger, S. L. and A. R. Kimmel eds. (1987) "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press; AK Patra et al. (2000) *Protein Expr Purif* 18(2):182-92; Kodama et al. (1986) *J. Biochem.* 99:1465-1472; Stewart et al. (1993) *Proc. Nat'l Acad. Sci. USA* 90:5209-5213; Lombillo et al. (1995) *J. Cell Biol.* 128:107-115; Vale et al. (1985) *Cell* 42:39-50.

EXAMPLES

Bacterial Strains and Growth Conditions.

Unless otherwise specified, all strains used for all *Pseudomonas* expression testing were based on *P. fluorescens* strain MB101. *E. coli* strains JM109 (Promega), XL2 Blue (Stratagene) or Top 10 (Invitrogen) were used for general cloning. For *E. coli* expression studies, BL21(DE3) Gold was used. *P. fluorescens* strains were grown in either LB or minimal salts medium supplemented with 15 ug/mL tetracycline and 30 ug/mL kanamycin as needed at 30°C. *E. coli* strains were grown in LB supplemented with 30 ug/mL kanamycin and/or 15 ug/mL chloramphenicol, or 15 ug/mL tetracycline as needed at 37°C. Cells were induced with 0.3mM IPTG following growth phase.

Protein Activity Detection (ELISA Assay)

Plates were coated by adding 200 µL of the β-galactosidase solution at 10 µg/mL in PBS (pH 7.6) to each well of the microtiter plate. Plates were incubated at room temperature for 16 hrs, then washed 3 times with 200 µL PBS + 0.1% Tween-20 (PBS-T). Primary antibody was diluted in PBS with 2% nonfat dry milk (w/v). 200 µL of the diluted antibody was added to each well and incubated at room temperature for 1 hr. The plates were then washed 4 times with 200 µL PBS-T. The secondary antibody was also diluted in PBS with 2% non fat dry milk (w/v) and to each well, 200 µL was added and incubated at room

temperature for 1.5-2 hours. The plates were then washed 4 times with PBS-T. A tertiary antibody is used to detect the scFv antibodies: alkaline phosphatase conjugated sheep anti-mouse antibody (Sigma-Aldrich, St. Louis, MO, USA cat #A5324). To each desired well was added 200 μ L of diluted antibody solution (or PBS-T) and incubated at room temperature for 1.5 hours. The plates were then washed 4 times with PBS-T. To each well was added 200 μ L of the freshly prepared Sigma Fast pNPP substrate (Sigma catalogue #R-2770). After 30 minutes, the reaction was stopped by adding 50 μ L 3M NaOH to each well and absorbance was read at 405 nm.

10 *Fermentation*

The inoculum for the fermentor culture for *P. fluorescens* is generated by inoculating a shake flask containing 600 mL of a chemically defined medium supplemented with yeast extract and dextrose. Tetracycline is typically added to ensure maintenance of the recombinant plasmid in the starter culture during its overnight incubation as well as in the fermentor. The shake flask culture is then aseptically transferred to a 20L fermentor containing a chemically defined medium designed to support a high biomass, without yeast extract supplementation. Oxygen is maintained at a positive level in the liquid culture by regulating the air flow into the fermentor and the agitator mixing rate; the pH is maintained at greater than 6.0 through the addition of aqueous ammonia. The fed-batch high density fermentation process is divided into an initial growth phase of approximately 24h and gene expression (induction) phase in which an inducer is added to initiate recombinant gene expression. Glucose, in the form of corn syrup, is fed throughout the fermentation process at limiting concentrations. The target cell density for initiating the induction phase is typically 150 OD units at 575nm. The induction phase of the fermentation is typically allowed to go for approximately 45 to 55 hours. During this phase, samples are withdrawn from the fermentor for various analyses to determine the level of target gene expression, cell density, etc.

For each fermentation experiment for *E. coli*, a frozen glycerol stock is removed from -80°C storage, thawed and diluted before inoculating a shake flask containing 600 mL of LB broth supplemented with kanamycin. The shake flask culture is incubated at 37°C with shaking at 300 rpm overnight and then aseptically transferred to a 20L fermentor containing complex medium. Temperature in the fermentor is maintained at 37°C, pH at 7 through the

addition of aqueous ammonia and phosphoric acid, and dissolved oxygen at greater than 20%. After a brief initial batch phase, glycerol is fed at rates increased stepwise to maintain excess carbon. When the cell density reaches 24-28 OD units at 600nm, recombinant expression is effected by addition of an inducer, such as isopropyl-thiogalactoside (IPTG). The induction
5 phase of the fermentation typically continues for approximately 3 to 5 hours as the fermentor reached volumetric capacity or as the growth rate began to decrease significantly. During this phase, samples are withdrawn from the fermentor for various analyses to determine the level of target gene expression, cell density, etc.

10 *Cell fractionation and SDS-PAGE analysis.*

Samples are normalized to A₅₇₅=30, and 1 mL normalized culture is pelleted. Cells are resuspended in 1mL lysis buffer (50 mM Tris base; 200mM NaCl; 5% v/v glycerol; 20 mM EDTA disodium salt; 0.5% v/v Triton X-100; 1 mM DTT). A protease inhibitor cocktail specific for bacterial lysates (Sigma#P8465) is added to a 1X concentration. The resuspended
15 cells are added to a 2 ml screw cap microfuge tube approximately ¾ full with 0.1 mm glass beads and the cells are mechanically lysed using 4, 1 minute incubations in a BioSpec bead mill at the highest setting. Cells are kept on ice between incubations. Approximately 100uL of lysed cell solution is removed from beads, transferred into a new tube and pelleted. The supernatant (soluble fraction) is removed to a new tube. The pellet (insoluble fraction) is
20 resuspended in an equal volume (100 uL) of lysis buffer plus protease inhibitor. Five uL of each sample is added to 5uL of 2X LDS loading buffer (Invitrogen) and loaded onto a 4-12% or 10% Bis-Tris NuPAGE gel (Invitrogen) and run in either 1X MES or 1X MOPS buffer as indicated.

Example 1: Expression of scFV in the Cytoplasm

25 Single chain antibody fragments (scFV) are finding increased use as diagnostic and therapeutic agents. These relatively small proteins are made by fusing together genes coding the variable light and heavy chains of an immunoglobulin.

Cloning of Gall3 scFv

The Gall3 scFv gene (Genbank accession number AF238290), cloned into the phage
30 display vector pCANTAB6, (see P Martineau et al. (1998) *J. Mol. Biol.* 280(1):117-27) was used as template to amplify a 774 base pair product, which was subsequently cloned into the

pCR2.1 TOPO vector (Invitrogen, Carlsbad, CA, USA). The scFv gene was excised from the TOPO vector with SpeI and SalI restriction enzymes (New England Biolabs, Beverly, MA, USA) and cloned into the SpeI and XhoI sites of the *P. fluorescens* vector pMYC1803, downstream of the Ptac promoter, to produce pDOW1117. The resulting plasmids were
 5 electroporated into *P. fluorescens*. The Gall3 gene was cloned into the pET24d+ expression vector (Novagen, Madison, WI, USA), following amplification such that SalI and NcoI sites flanked the coding sequence. The PCR products were digested with SalI and NcoI and cloned into the same sites of pET24d+ vector downstream of the T7 promoter. The newly formed
 10 construct was then used to transform XL2 Blue competent cells. Once sequence was confirmed, the DNA construct was used to transform BL21(DE3) Gold (Stratagene, San Diego, CA, USA) for expression.

Expression of a Single Chain Antibody Fragment (scFv) in E. coli and P. fluorescens

scFv molecules were expressed in both *E. coli* and *P. fluorescens*, among them an
 15 scFv with binding activity to the *E. coli* protein β -galactosidase single chain antibody gal13 (P. Martineau et al., "Expression of an antibody fragment at high levels in the bacterial cytoplasm, " J. Mol. Biol. 280(1):117-27 (1998)). *P. fluorescens* expressed about six-fold more protein than *E. coli* during 20L fermentation, with 3.1 g/L yield in *P. fluorescens* and 0.5 g/L yield in *E. coli* as determined by SDS-PAGE and densitometry (see Table 8). *P.*
 20 *fluorescens* expressed about 96% soluble protein, whereas *E. coli* expresses only 48% soluble protein.

Table 8: Gall3 fermentation summary (*compared to BSA standards)

	<i>E. coli</i>	<i>P. fluorescens</i>	<i>Pf/Ec</i>
Fermentatino Time (hr)	8-9	70	8
Max hGH titre (*g/L)	0.4 (85%cv)	3.1 (24%cv)	8
Dry biomass (g/L)	ND (30)	59	(2)
hGH/biomass (%w/w)	(1)	5	(5)

Material purified from both expression systems was found to be active in an enzyme-linked
 25 immunosorbant assay (ELISA) as shown in Figure 2. Material was also purified from the soluble fraction only of equal lysate volumes from lysates of both strains using affinity chromatography. Finally, the overall volumetric recovery for the *P. fluorescens* process is approximately 20 fold more efficient than for *E. coli*, 1.34 g/L vs. 0.07 g/L.

Example 2: Expression of human γ -IFN in the Cytoplasm

Cloning of Human gamma-Interferon

Human gamma interferon (hu- γ IFN, Genbank accession X13274) was amplified from
5 a human spleen cDNA library (Invitrogen, Carlsbad, CA, USA; catalogue #10425-015) such
that it lacked the native secretion signal, with the N-terminus of the recombinant γ -IFN
beginning as Met-Cys-Tyr-Cys-Gln-Asp-Pro as described in PW Gray et al. (1982) *Nature*
298:859-63. The resulting product was cloned into the pCR2.1 TOPO vector and the
sequence was confirmed. The hu- γ IFN gene was excised from the TOPO vector with SpeI
10 and XhoI restriction enzymes and cloned into the same sites of pMYC1803. In a separate
reaction, hu- γ IFN was amplified such that AflIII and XhoI sites flanked that coding sequence.
The resulting fragment was cloned into the TOPO-TA vector (Invitrogen) and transformed
into chemically competent *E. coli* JM109 cells (Promega, Madison, WI, USA). The gene was
isolated by digesting with AflIII and XhoI (New England Biolabs), cloned into the NcoI and
15 XhoI sites of pET24d+ (Novagen, Madison, WI, USA) downstream of the T7 promoter, and
transformed into JM109. A positive clone was transformed into *E. coli* BL21(DE3) cells
(Novagen) to test for expression.

Human gamma-Interferon Purification

20 Frozen cell paste from *P. fluorescens* cultures was thawed and re-suspended in lysis
buffer (50 mM potassium phosphate, pH 7.2 containing 50 mM NaCl, 10 mM EDTA
(ethylenediaminetetraacetic acid, catalog number BP118-500, Fisher Scientific, Springfield,
NJ, USA), 1 mM PMSF (phenylmethylsulfonyl fluoride, catalog number P-7626, Sigma, St.
Louis, MO), 1mM dithiothreitol (catalog number D-0632, Sigma), and 1 mM benzamidine
25 (catalog number B-6506, Sigma)) at a ratio of about 1 gram cell paste per 2 mL lysis buffer.
Cells were broken by three passages through a microfluidizer (model 110Y, Microfluidics
Corporation, Newton, MA, USA). Cell debris and unbroken cells were removed by
centrifugation (for 60 min at 23,708 x g and 4°C using a Beckman Coulter centrifuge; model
JA 25.50, Beckman Coulter, Inc., Fullerton, CA, USA). The resulting supernatant (cell-free
30 extracts) was clarified by adding 10% w/v diatomaceous earth (Celite product, World
Minerals, Inc., Goleta, CA, USA) and passing the result through a paper filter (Whatman 1,

catalog number 1001-150, Whatman Paper Ltd., Maidstone, Kent, UK)) with vacuum filtration.

Clarified cell extracts were applied to a 3.2 cm x 13.5 cm chromatography column of SP-Sepharose FAST FLOW (6% cross-linked agarose bead material; catalog number 17-0709-10, Amersham Biosciences, Piscataway, NJ, USA) equilibrated in buffer A, at a flow rate of 0.5 mL/min. The composition of Buffer A was: 50mM HEPES, pH 7.8 (i.e. N-(2-hydroxyethyl)piperazine)N'-(2-ethanesulfonic acid), from Fisher Scientific, catalog number BP-310-100), 50mM NaCl, 1mM EDTA, and 0.02% sodium azide (catalog number 71289, Sigma Chemical Co.). After loading, the column was washed with 3 column volumes (column volume = 108 mL) buffer A and 5 column volumes of buffer A containing 0.4M NaCl. The column was further developed by applying a gradient of 0.4 M to 1 M NaCl in the same buffer at a flow rate of 2 mL/min for a total of 7 column volumes. Fractions containing pure IFN- γ were then pooled and dialyzed against 1X PBS (phosphate-buffered saline, pH 7.2) at 4°C. Protein was concentrated by ultrafiltration (using a YM30 ultrafiltration membrane; catalog no. 13722, from Millipore, Bedford, MA USA), then frozen in liquid nitrogen and stored at -80°C.

Expression of Human γ -Interferon in E. coli and P. fluorescens

Human γ -interferon is produced commercially by fermentation of *E. coli* expressing the γ -IFN gene. The protein is expressed cytoplasmically in an insoluble and inactive form. In order to produce the recombinant polypeptide as an active pharmaceutical ingredient, the interferon must be recovered, solubilized, refolded, and then purified. All these unit operations add greatly to the cost of goods (COGs) for this protein. A human spleen cDNA library was used as a template to amplify the γ IFN cDNA without the native signal sequence and clone into *E. coli* and *P. fluorescens* expression vectors. *P. fluorescens* construct produced ~4g/L of γ IFN protein during a typical 20L fermentation reaction. SDS-PAGE and Western analyses of soluble and insoluble fractions show that the majority of the protein (95%) is present in the soluble fraction. Figure 1 shows that hu- γ -IFN purified from the soluble fraction of *P. fluorescens* samples displays activity comparable to a commercially available standard. Figure 5 and Table 9 show a comparison of expression of γ -IFN between *E. coli* and *P. fluorescens* expression systems.

Table 9: γ -IFN fermentation summary (*compared to BSA standards)

	<i>E. coli</i>	<i>P. fluorescens</i>	<i>Pf/Ec</i>
Fermentatino Time (hr)	7-9	55	6
Max hGH titre (*g/L)	3.9	4.5	1.5
Dry biomass (g/L)	~22	100	4.5
hGH/biomass (%w/w)	~17.7	4.5	0.25

Assay of Human gamma Interferon Activity

Cell lines and media: HeLa cells (catalogue no. CCL-2) and encephalomyocarditis virus (ECMV, catalogue no. VR-129B) were obtained from the American Type Culture Collection (Manassas, VA). HeLa cells were maintained in Eagles Modified Essential Medium (Cellgro EMEM, Mediatech, Herdon, VA, USA) with 10% fetal bovine serum (Gibco, Invitrogen, Carlsbad, CA, USA) at 37°C/ 5% CO₂.

The activity of purified hu- γ IFN was assayed using a viral inhibition assay as previously described (JA Lewis (1987) in *Lymphokines and Interferons: A Practical Approach* MJ Clemens et al. (eds.) (IRL Press Ltd, Oxford, England). Briefly, HeLa cells were seeded in a 96-well microtiter plate at 3×10^4 per well. After 24 hours, purified hu- γ IFN isolated from *P. fluorescens*, or *E. coli* recombinant hu- γ IFN (from R&D Systems, Minneapolis, MN, USA), was added to triplicate wells at 0, 0.01 or 0.05 ng per well. After preincubating the cells with hu- γ IFN for 24 hours, ECMV was added at varying dilutions to sets of triplicate wells. The cells were incubated for 5 days, after which cell viability was measured using a cell proliferation ELISA that monitors 5-bromo-2'-deoxyuridine incorporation (catalogue no. 1647229, Roche Molecular Biochemicals, Indianapolis, IN, USA). Results are expressed as absorbance units, with greater absorbance resulting from the presences of a greater number of actively dividing (live) cells.

Example 3: Expression of hGH in the Cytoplasm

Primers were designed to amplify human growth hormone (hGH) from human cDNA libraries. For this study, hGH was amplified using AmpliTaq polymerase (Perkin Elmer) according to the manufacturer's protocol, using the above plasmid as template and primers ELVirev and hgh-sig, with a PCR cycling profile of 95°C 2 minutes (95°C 60 seconds 42°C 120 seconds 72°C 3 minutes) 25X. The resulting product was purified using Wizard PCR DNA purification kit (Promega), digested with SpeI and XhoI restriction enzymes (New

England Biolabs) and cloned into the same sites of pMYC1803 (see Figure 3). A mutation found in the amplified hGH was corrected by using the hgh-sigcorr primer with ELVlrev and repeating the PCR and cloning procedures.

Primers used to clone hGH.

hGH-sig	AGAGAACTAGTAAAAAGGAGAAATCCATGTTCCCAACCATTCCTT ATC
HGH-sigcorr	AGAGAACTAGTAAAAAGGAGAAATCCATGTTCCCAACCATTCCTT ATCCAGGCCTTTTGAC
ELVIfor	AGAGAACTAGTAAAAAGGAGAAATCCATGGCTACAGGCTCCCGGA CGTCC
ELVlrev	AGAGACTCGAGTCATTAGAAGCCACAGCTGCCCTCCAC

5

Purification of hGH

Following 20L fermentation, hGH was purified from the insoluble fraction of *E. coli* and *P. fluorescens* cells, with the exception that during DEAE FF elution a gradient from 0 to 0.5M NaCl was used in place of a 0.25M NaCl step.

10

Expression of human growth hormone in E. coli vs. P. fluorescens.

The cDNA encoding human growth hormone was amplified from a human pituitary cDNA library. The native secretion signal sequence was removed, and an N-terminal methionine was engineered into the constructs for microbial expression. For *E. coli* expression, the pET25 vector containing the hGH gene was transformed into BL21(DE3), which contains an integrated T7 polymerase gene necessary for hGH transcription. *P. fluorescens* expression studies were carried out in the MB214 strain, which contains an integrated lacI gene to control expression from the Ptac promoter. Both expression systems were evaluated at the 20L fermentation scale. As shown in Table 10, *P. fluorescens* (Pf) outperformed *E. coli* (EC) in the amount of protein produced per gram of dry biomass (1.6X as much).

15

20

*Table 10: hGH fermentation summary (*compared to BSA standards)*

	<i>E. coli</i>	<i>P. fluorescens</i>	<i>Pf/Ec</i>
Fermentatino Time (hr)	7-9	55	6
Max hGH titre (*g/L)	2.6 (23%cv)	7.3 (5%cv)	3
Dry biomass (g/L)	37	66	2
hGH/biomass (%w/w)	7	11	1.6

Cell fractionation and SDS-PAGE analysis show that hGH is found in the insoluble fraction in both expression systems (Figure 4). Surprisingly, approximately 7X more hGH monomer was purified from *P. fluorescens*, compared to *E. coli*, despite a difference of only 1.6X in protein production per gram of dry biomass.

5 Table 11.-Comparison of hGH purification from *E. coli* and *P. fluorescens*

1.62-1.75 L portion of <i>P. fluorescens</i> containing rh-GH			
	Wet Biomass (wet g)	Purified Monomer (mg)	Purified Dimer (mg)
Soluble	minimal	NA	NA
Lipid Extract	None detected	--	--
Lipid Insoluble	62.2-63.1	1483	346

1.5-1.6 L portion of <i>E. coli</i> containing rh-GH			
	Wet Biomass (wet g)	Purified Monomer (mg)	Purified Dimer (mg)
Soluble	minimal	NA	NA
Lipid Extract	None detected	--	--
Lipid Insoluble	35.0	200	333

Example 4: Expression of Proteins in the Periplasm

Characterization of Secretion Signal Peptides

10 *Pseudomonas fluorescens* secretion signal peptides were discovered by formation and expression of alkaline phosphatase (phoA) coding sequence-genomic DNA fusions and are described in more detail in U.S. Application No. 10/996,007, filed November 22, 2004. Six of the expressed fusions were further characterized as follows.

The cleavage site for the signal sequences for the secreted genes identified as
 15 phoA fusions was deduced by comparison to homologous proteins from other Pseudomonads, by the SPScan program (Menne *et al*, 2000). The cleavage site of the putative lipoprotein was deduced by comparison to signal peptidase II motifs; signal peptidase II specifically cleaves the signal sequences of lipoproteins. All six of the signal peptides were analyzed using SignalP (a software program for analysis of putative signal
 20 peptides; available from the Center for Biological Sequence Analysis of the Technical University of Denmark. Also see, Nielson *et al*. (1997) *Protein Engineering* 10: 1-6. In some cases, a supplementary source was used to further characterize the identity of the signal peptide. This information is present in Table 12.

Table 12. Identities of Secretion Signal Peptides

Identity	Putative Amino Acid Sequence
Putative porin El precursor, OprE	Lys Lys Ser Thr Leu Ala Val Ala Val Thr Leu Gly Ala Ile Ala Gln Gln Ala Gly Ala
Putative phosphate binding protein	Lys Leu Lys Arg Leu Met Ala Ala Met Thr Phe Val Ala Ala Gly
Putative azurin	Phe Ala Lys Leu Val Ala Val Ser Leu Leu Thr Leu Ala Ser Gly Gln Leu Leu Ala
Putative periplasmic lipoprotein B precursor	Ile Lys Arg Asn Leu Leu Val Met Gly Leu Ala Val Leu Leu Ser
Putative Lys-Arg-Orn binding protein	Gln Asn Tyr Lys Lys Phe Leu Leu Ala Ala Ala Val Ser Met Ala Phe Ser Ala Thr Ala Met Ala
Putative Fe(III) binding protein	Met Ile Arg Asp Asn Arg Leu Lys Thr Ser Leu Leu Arg Gly Leu Thr Leu Thr Leu Leu Ser Leu Thr Leu Leu Ser Pro Ala Ala His Ser

Western analysis of the phoA fusion proteins to detect fusion proteins

To analyze whether the fusion proteins were produced, Western analysis with antibody to alkaline phosphatase was carried out on cultures separated by centrifugation into a whole-cell fraction (cytoplasm and periplasm) and a cell-free broth fraction. Of five strains for which the site of insertion was determined, four (putative azurin, putative phosphate binding protein, putative periplasmic lipoprotein B, putative Fe(III) binding protein) produced a fusion protein of the expected size, and one (putative oprE protein) produced a protein about 40 kD smaller than predicted, and one (putative Lys-Arg-Orn binding protein) produced a protein about 20 kD smaller than predicted.

Proteins were separated by SDS-PAGE and were transferred to nitrocellulose membrane at 40 V for one hour using the Xcell SureLock™ Mini-Cell and XCell II™ Blot Module (Invitrogen). Western experiments were performed using the instruction provided from SuperSignal West HisProbe™ Kit (Pierce).

Construction, Expression, and Characterization of a pbp-hGH Fusion

The *P. fluorescens* phosphate binding protein secretion leader was fused to the N-terminus of the mature domain of the human growth hormone (hGH) gene and tested for expression and secretion.

The pbp signal-sequence coding region was PCR amplified from a clone of the *P. fluorescens* pbp signal sequence as template, using sig_pbp for (gctctagaggaggttaacttatgaaactgaaacg) and pbp_hgh (gggaatggttggaaggccaccgcgttggc)

primers, then gel-purified. This resulted in production of an oligonucleotide fragment containing the pbp signal peptide CDS and the coding sequence for the 5' end of the mature domain of hGH.

A cDNA encoding the human growth hormone was PCR-amplified from a human
 5 pituitary cDNA library (Clontech, Palo Alto CA) using primers ELVIfor
 (agagaactagtaaaaaggagaaatccatggctacaggctcccggacgtcc) and ELVIrev
 (agagactcgagtcattagaagccacagctgccctccac), which were designed to amplify only the mature
 domain of hGH, and cloned into pMYC1 803/SpeI XhoI, forming pDOW2400. The mature
 hGH gene was amplified from pDOW2400, using primers pbp_hgh_revcomp
 10 (gccaacgcggtggccttcccaaccattccc) and hgh_rev (agagactcgagtcattagaagc
 cacagctgccctccacagagcggcac), then purified with Strataprep columns (Stratagene) to remove
 primers and other reaction components. To make the polynucleotide encoding the pbp-hGH
 fusion, the two PCR reactions were combined and amplified again with sig_pbp for and
 hgh_rev in order to link the two pieces. The expected 681 bp fragment was purified with
 15 Strataprep as above, restriction digested with XbaI and XhoI and ligated to dephosphorylated
 pDOW1269/XhoISpeI to form pDOW 1323-10, placing pbp-hGH under control of the tac
 promoter in a vector analogous to pMYC1803, but with a pyrF selectable marker in place of a
 tetR tetracycline resistance marker gene. The ligation mix was transformed into MB101 pyrF
 proC lacI^{Q1}. Inserts were sequenced by The Dow Chemical Company using the method
 20 described above. The DNA and amino acid sequence of this fusion is presented in (Figure 10)
 and (Figure 11), respectively.

The resulting strains were tested first at the shake flask scale. Induced bands of the
 expected size for processed and unprocessed (22.2 kDa and 24.5 kDa, respectively) were
 detected by SDS-PAGE. About half of the protein was processed (indicating localization to
 25 the periplasm), and of the processed about half was in the soluble fraction and half in the
 insoluble fraction. Expression studies were scaled up to 20-L bioreactors. Densitometry of
 the Coomassie-stained SDS-PAGE gels showed that 18% of the total hGH produced was
 processed and soluble. The strain produced 3.2 g/L of all forms of hGH; processed and
 soluble was 0.6 g/L.

30

Construction, Expression, and Characterization of pbp-scFv Fusion

The putative 24 amino acid signal sequence of phosphate binding protein (i.e. including Met1) was fused to the open reading frame of the gal2 scFv gene (gal2) at the +2 amino acid (Ala) position. See Figure 8 and Figure 9. The signal sequence appears to be processed, indicating secretion to the periplasm. Moreover, there is secretion to the broth, in that protein was detected in the cell free culture supernatant. Surprisingly, fusion to the phosphate binding protein signal sequence appears to improve expression of gal2 scFv in *P. fluorescens*. Without the secretion signal fused at the amino terminus, expression of gal2 scFv was not detectable.

Cloning of Gal2

PCR was performed using primers sig_pbp for (above) and pbp_gal2SOE rev (ctgcacctgggcgccaccgcgtt), which contains a reverse complement of pbp_gal2SOE for (aaccgcggtggccgccaggtgcag), and using a plasmid encoding the *P. fluorescens* pbp secretion signal peptide as template. This resulted in production of an oligonucleotide fragment containing the pbp signal peptide coding sequence (CDS) and a CDS for the 5' end of the gal2 single chain antibody (scAb or scFv).

PCR was performed using primers pbp_gal2SOE for and scFv2rev (acgcgtcgacttattaatggtg atgatggtgatgtgcggccgcacgtttgatc), and using a gal2-encoding polynucleotide as template. This resulted in production of a polynucleotide fragment containing a CDS encoding the 3' end of the pbp signal peptide and the open reading frame (ORE) encoding gal2.

Reaction products were purified. About 15ng of each was used as a "template" DNA in a further PCR reaction using primers sig_pbp_for and scFv2rev. This resulted in production of a nucleic acid fragment with the pbp signal peptide CDS fused to the gal2 coding sequence.

The predicted -1 amino acid of the signal sequence (that is the last amino acid prior to the proposed cleavage site) was fused to the +2 amino acid of the gal2 scFv (Ala). The resulting fusion was cloned into the *P. fluorescens* vector pMYC1803 under control of the Ptac promoter to produce plasmid and pDOW1123 (pbp:gal2). The plasmid was transformed into *P. fluorescens* strain MB 101 carrying plasmid pCN51-lacI (described in U.S. Application No. 10/994,138, filed November 19, 2004).

Fusion of the putative phosphate binding protein signal sequence to gal2 scFv

The phosphate binding protein signal sequence was fused to a single chain antibody gene and tested for secretion to the periplasm and/or to the culture supernatant.

5 *Table 13: secreted Gal2 fermentation summary (*compared to BSA standards)*

	<i>E. coli</i>	<i>P. fluorescens</i>	<i>Pf/Ec</i>
Fermentation Time (hr)	8-9	50-70	8
Max hGH titre (*g/L)	1.6 (0.8 processed)	9.3 (25%cv)	6(12)
Dry biomass (g/L)	18	(70)	4
hGH/biomass (%w/w)	8.9 (4.4 processed)	13	1.5 (3)

10 The resulting strains were tested first at the shake flask scale. Induced bands of the expected size for unprocessed and processed gal2 (29kDa and 27kDa) were detected via SDS-PAGE in the insoluble protein fraction (data not shown). Expression studies were scaled up to 20L fermentation. Again, SDS-PAGE analysis showed that the majority of the induced protein is found in the insoluble protein fraction.

15 The Western analysis also indicated that some processed gal2 is present in the soluble protein fraction for pbp:gal2 (pDOW1123). Western analysis of periplasmic fractions prepared from strains carrying pDOW 1123 (using the Epicentre periplast kit) showed the presence of soluble gal2 protein.

Recombinant gal2 scFv was isolated from the cell extract of a shake flask experiment using the Qiagen Ni-NTA protocol, then refolded as described in P. Martineau et al., J Mol. Biol. 280:117-127 (1998). This antibody was found to be active against β -galactosidase in an ELISA assay.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

WHAT IS CLAIMED IS:

- 1) A method for producing a recombinant human or murine protein in a *Pseudomonas fluorescens* host cell comprising:

transforming a *Pseudomonas fluorescens* host cell with a nucleic acid encoding a recombinant human or murine protein; and

growing the cell under conditions that allow expression of the recombinant human or murine protein,

wherein the recombinant human or murine protein is present in the host cell in a soluble form, wherein the soluble recombinant human or murine protein is expressed at an increased level when compared to an expression level of the protein under substantially comparable conditions in an *E.coli* expression system, and wherein the recombinant human or murine protein is an antibody.
- 2) The method of Claim 1, further comprising isolating the recombinant human or murine protein.
- 3) The method of any one of Claim 1 or 2, further comprising substantially purifying the recombinant human or murine protein.
- 4) The method of any one of Claims 1 to 3, wherein the recombinant human or murine protein is present in the cell in an active form.
- 5) The method of any one of Claims 1 to 4, wherein the recombinant human or murine protein is produced at a concentration of at least 10g/L.
- 6) The method of any one of Claims 1 to 5, wherein the recombinant human or murine protein has a mass of between 1 kD and 500 kD.
- 7) The method according to any one of Claims 1 to 6, wherein said nucleic acid encoding the antibody comprises at least two expression vectors.
- 8) The method according to Claim 7, wherein said at least two expression vectors comprise a first promoter-cistron pair and a second promoter-cistron pair.
- 9) The method according to Claim 8, wherein said first promoter-cistron pair is an immunoglobulin light chain and said second promoter-cistron pair is an immunoglobulin heavy chain.

- 10) The method according to Claim 9, wherein the light chain and heavy chain are located on the same vector.
- 11) The method according to any one of Claims 9 to 10, wherein said first or second promoter-cistron pair further comprises a translation initiation region operably linked to the nucleic acid encoding an antibody.
- 12) The method according to Claim 11, wherein the translation initiation region provides different translational strengths to the first and second promoter-cistron pair.
- 13) The method according to any one of Claims 1 to 6, wherein said nucleic acid encodes an antibody or antibody fragment comprising at least two separate translational units and further wherein the translational units are expressed in sequential fashion
- 14) The method according to Claim 13, wherein said at least two separate translational units comprise a light chain and a heavy chain.
- 15) The method according to any one of Claims 1 to 14, wherein said antibody is a single chain antibody, a full chain antibody, or an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, F(ab')₂-leucine zipper, Fv, dsFv, and anti-CD18 antibody.
- 16) The method according to Claim 15, wherein said Fab fragment comprises a light and a heavy chain fragment.
- 17) The method according to any one of Claims 15 to 16, wherein said Fab comprises an antigen binding site.
- 18) The method according to any one of Claims 1 to 17, wherein said antibody or antibody fragment is a chimeric antibody, human antibody or humanized antibody.
- 19) The method according to any one of Claims 1 to 18, wherein said method further comprises linking a secretion signal sequence to said antibody.
- 20) The method according to any one of Claims 1 to 19, wherein said antibody further comprises an Fc region.
- 21) The method according to any one of Claims 1 to 20, wherein said antibody is a fusion protein.

- 22) The method according to claim 15, wherein the recombinant human or murine protein is a single chain antibody.
- 23) The method according to any one of Claims 1 to 22, wherein said antibody or antibody fragment target antigen is Complement C5, CBL, CD147, IL-8, HIV gp120, VLA-4, CD11a, CD18, VEGF, CD40L, anti-Id, ICAM-1, CD2, EGFR, TGF- β 2, TNF- α , E-selectin, Factor VII, Her2, F glycoprotein, CD14, ICAM-3, CD80, CD4, CD23, β 2-integrin, α 4 β 7, CD52, HLA DR, CD22, CD64, CD2, CD3, Hepatitis B antigen, CA 125, EpCAM, gpIIbIIIa, CD20, IL5, IL4, CD25, CD33, HLA, or VNR integrin.
- 24) The method according to any one of Claims 1 to 22, wherein said antibody or antibody fragment target antigen is Complement C5, CBL, CD147, CD11a, CD18, VEGF, CD40L, CD2, CD14, CD80, CD4, CD23, CD52, CD22, CD64, CD2, CD3, CD20, CD25, or CD33.
- 25) The method according to any one of Claims 1 to 22, wherein said antibody or antibody fragment target antigen is IL-8, IL5, or IL4.
- 26) The method according to any one of Claims 1 to 22, wherein said antibody or antibody fragment target antigen is VEGF, EGFR, TGF- β 2, TNF- α , Her2, or F glycoprotein.
- 27) The method according to any one of Claims 1 to 22, wherein said antibody or antibody fragment target antigen is VEGF.
- 28) The method according to any one of Claims 1 to 27, wherein the antibody or antibody fragment is a single-chain antibody, and wherein the single-chain antibody is for therapeutic use.
- 29) The method according to any one of Claims 1 to 27, wherein the antibody or antibody fragment is a single-chain antibody, and wherein the single-chain antibody is for diagnostic use.
- 30) The method according to any one of Claims 1 to 29, wherein the soluble recombinant human or murine protein is produced as 1-75% total cell protein.
- 31) The method according to claim 30, wherein the soluble human or murine protein is produced as 5-75% total cell protein.




FIGURE 1




FIGURE 2

A.

MFPTIPLSRPFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESI
 PTPSNREETQQKSNLELLRLISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDL
 EEGIQTLMGRLDGSPRTGQIFKQTYSKFDTNSHNDALLKNYGLLYCFRKMMDKVE
 TFLRIVQCRSVEGSCGF

B.




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

```

agagaactagtaaaaaggagaaatccATGCAGGGCCAATTTTTTAGA
1  -----+-----+-----+-----+----- 47
tctcttgatcatttttctctcttaggTACGTCCCGGTAAAAAATCT

      M  Q  G  Q  F  F  R

GAAATAGAAAACCTTAAAGGAGTATTTTAATGCAAGTAGCCCAGATGTAGCTAAGGGTGGG
48  -----+-----+-----+-----+-----+ 107
CTTTATCTTTTGAATTTCCTCATAAAATTACGTTTCATCGGGTCTACATCGATTCCCACCC

E  I  E  N  L  K  E  Y  F  N  A  S  S  P  D  V  A  K  G  G

CCTCTCTTCTCAGAAATTTTGAAGAATTGGAAAGATGAAAGTGACAAAAAATTATTCAG
108 -----+-----+-----+-----+-----+ 167
GGAGAGAAGAGTCTTTAAAACTTCTTAACCTTTCTACTTTCACGTGTTTTTTTAATAAGTC

P  L  F  S  E  I  L  K  N  W  K  D  E  S  D  K  K  I  I  Q

AGCCAAATTGTCTCCTTCTACTTCAAACCTTTGAAAACCTCAAAGATAACCAGGTCATT
168 -----+-----+-----+-----+-----+ 227
TCGGTTTAACAGAGGAAGATGAAGTTTGAGAACTTTTGGAGTTTCTATTGGTCCAGTAA

S  Q  I  V  S  F  Y  F  K  L  F  E  N  L  K  D  N  Q  V  I

CAAAGGAGCATGGATATCATCAAGCAAGACATGTTTCAGAAGTTCTTGAATGGCAGCTCT
228 -----+-----+-----+-----+-----+ 287
GTTTCCTCGTACCTATAGTAGTTCGTTCTGTACAAAGTCTTCAAGAACTTACCGTCGAGA

Q  R  S  M  D  I  I  K  Q  D  M  F  Q  K  F  L  N  G  S  S

GAGAACTGGAGGACTTCAAAAAGCTGATTCAAATTCCGGTGGATGATCTGCAGATCCAG
288 -----+-----+-----+-----+-----+ 347
CTCTTTGACCTCCTGAAGTTTTTCGACTAAGTTTAAGGCCACCTACTAGACGTCTAGGTC

E  K  L  E  D  F  K  K  L  I  Q  I  P  V  D  D  L  Q  I  Q

CGCAAAGCCATAAATGAACTCATCAAAGTGATGAATGACCTGTCACCAAATCTAACCTC
348 -----+-----+-----+-----+-----+ 407
GCGTTTCGGTATTTACTTGAGTAGTTTCACTACTTACTGGACAGTGGTTTTAGATTGGAG

R  K  A  I  N  E  L  I  K  V  M  N  D  L  S  P  K  S  N  L

AGAAAGCGGAAGAGAAGTCAGAATCTCTTTCGAGGCCGGAGAGCATCAACGtaatgactcgagtctct
408 -----+-----+-----+-----+-----+ 475
TCTTTCGCCTTCTCTTCAGTCTTAGAGAAAGCTCCGGCCTCTCGTAGTTGCattactgagctcagaga

R  K  R  K  R  S  Q  N  L  F  R  G  R  R  A  S  T  *

```

FIGURE 7

atg aaa ctg aaa cgt ttg atg gcg gca atg act ttt gtc gct gct ggc Met Lys Leu Lys Arg Leu Met Ala Ala Met Thr Phe Val Ala Ala Gly 1 5 10 15	48
gtt gcg acc gcc aac gcg gtg gcc gcc cag gtg cag ctg cag gag tcg Val Ala Thr Ala Asn Ala Val Ala Ala Gln Val Gln Leu Gln Glu Ser 20 25 30	96
ggc cca gga ctg gtg aag cct tcg gag acc ctg tcc ctc acc tgc act Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr 35 40 45	144
gtc tct ggt ggt tcc atc agt agt tat cac tgg agc tgg atc cgg cag Val Ser Gly Gly Ser Ile Ser Ser Tyr His Trp Ser Trp Ile Arg Gln 50 55 60	192
ccc cca ggg aag gga ctg gag tgg att ggg tat atc tat tac agt ggg Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly 65 70 75 80	240
agc acc aac tac aac ccc tcc ctc aag aat cga gtc acc ata tct gta Ser Thr Asn Tyr Asn Pro Ser Leu Lys Asn Arg Val Thr Ile Ser Val 85 90 95	288
gac acg tcc aag aac cag ttc tcc ctg aac ctg agg tct gtg acc gct Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Arg Ser Val Thr Ala 100 105 110	336
gca gac acg gcc gtg tat tac tgt gcg cga gga acg tat ggc cca gcc Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Gly Pro Ala 115 120 125	384
gga gat gct ttt gat atc tgg ggg caa ggg acc acg gtc acc gtc tcg Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser 130 135 140	432
agt ggt gga ggc ggt tca ggc gga ggt ggc agc ggc ggt ggc gga tcg Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 145 150 155 160	480
gac atc cag atg acc cag tct cct tcc acc ctg tct gca tct att gga Asp Ilr Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly 165 170 175	528
gac aga gtc acc atc acc tgc cgg gcc agt gag ggt att tat cac tgg Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Gly Ile Tyr His Trp 180 185 190	576
ttg gcc tgg tat cag cag aag cca ggg aaa gcc cct aaa ctc ctg atc Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 195 200 205	624
tat aag gcc tct agt tta gcc agt ggg gcc cca tca agg ttc agc ggc Tyr Lys Ala Ser Ser Leu Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly 210 215 220	672
agt gga tct ggg aca gat ttc act ctc acc atc agc agc ctg cag cct Ser Gly Ser Gly Thr Asp Phe Thr Leu The Ile Ser Ser Leu Gln Pro 225 230 235 240	720
gat gat ttt gca act tat tac tgc caa caa tat agt aat tat ccg ctc Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Leu 245 250 255	768
act ttc ggc gga ggg acc aag ctg gag atc aaa cgt gcg gcc gca cat Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala His 260 265 270	816
cac cat cat cac cat taa His His His His 275	834

FIGURE 8

Met Lys Leu Lys Arg Leu Met Ala Ala Met Thr Phe Val Ala Ala Gly
 Val Ala Thr Ala Asn Ala Val Ala Ala Gln Val Gln Leu Gln Glu Ser
 20 25 30
 Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr
 35 40 45
 Val Ser Gly Gly Ser Ile Ser Ser Tyr His Trp Ser Trp Ile Arg Gln
 50 55 60
 Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly
 65 70 75 80
 Ser Thr Asn Tyr Asn Pro Ser Leu Lys Asn Arg Val Thr Ile Ser Val
 85 90 95
 Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Arg Ser Val Thr Ala
 100 105 110
 Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Gly Pro Ala
 115 120 125
 Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 130 135 140
 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 145 150 155 160
 Asp Ilr Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Ile Gly
 165 170 175
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Gly Ile Tyr His Trp
 180 185 190
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 195 200 205
 Tyr Lys Ala Ser Ser Leu Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly
 210 215 220
 Ser Gly Ser Gly Thr Asp Phe Thr Leu The Ile Ser Ser Leu Gln Pro
 225 230 235 240
 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Tyr Pro Leu
 245 250 255
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala His
 260 265 270
 His His His His His
 275

FIGURE 9

atg aaa ctg aaa cgt ttg atg gcg gca atg act ttt gtc gct gct ggc Met Lys Leu Lys Arg Leu Met Ala Ala Met Thr Phe Val Ala Ala Gly 1 5 10 15	48
gtt gcg acc gcc aac gcg gtg gcc ttc cca acc att ccc tta tcc agg Val Ala Thr Ala Asn Ala Val Ala Phe Pro Thr Ile Pro Leu Ser Arg 20 25 30	96
cct ttt gac aac gct atg ctc cgc gcc cat cgt ctg cac cag ctg gcc Pro Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala 35 40 45	144
ttt gac acc tac cag gag ttt gaa gaa gcc tat atc cca aag gaa cag Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln 50 55 60	192
aag tat tca ttc ctg cag aac ccc cag acc tcc ctc tgt ttc tca gag Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu 65 70 75 80	240
tct att ccg aca ccc tcc aac agg gag gaa aca caa cag aaa tcc aac Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn 85 90 95	288
cta gag ctg ctc cgc atc tcc ctg ctg ctc atc cag tcg tgg ctg gag Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln Ser Trp Leu Glu 100 105 110	336
ccc gtg cag ttc ctc agg agt gtc ttc gcc aac agc ctg gtg tac ggc Pro Val Gln Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly 115 120 125	384
gcc tct gac agc aac gtc tat gac ctc cta aag gac cta gag gaa ggc Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly 130 135 140	432
atc caa acg ctg atg ggg agg ctg gaa gat ggc agc ccc cgg act ggg Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly 145 150 155 160	480
cag atc ttc aag cag acc tac agc aag ttc gac aca aac tca cac aac Gln Ile Phe Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn 165 170 175	528
gat gac gca cta ctc aag aac tac ggg ctg ctc tac tgc ttc agg aag Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys 180 185 190	576
gac atg gac aag gtc gag aca ttc ctg cgc atc gtg cag tgc cgc tct Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser 195 200 205	624
gtg gag ggc agc tgt ggc ttc taa Val Glu Gly Ser Cys Gly Phe 210 215	648

FIGURE 10

Met Lys Leu Lys Arg Leu Met Ala Ala Met Thr Phe Val Ala Ala Gly
 1 5 10 15
 Val Ala Thr Ala Asn Ala Val Ala Phe Pro Thr Ile Pro Leu Ser Arg
 20 25 30
 Pro Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala
 35 40 45
 Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln
 50 55 60
 Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu
 65 70 75 80
 Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn
 85 90 95
 Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln Ser Trp Leu Glu
 100 105 110
 Pro Val Gln Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly
 115 120 125
 Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly
 130 135 140
 Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly
 145 150 155 160
 Gln Ile Phe Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn
 165 170 175
 Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys
 180 185 190
 Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser
 195 200 205
 Val Glu Gly Ser Cys Gly Phe
 210 215

FIGURE 11